Longitudinal omics in Syrian hamsters integrated with human data unravel cellular effector responses to moderate COVID-19

Geraldine Nouailles (✉ geraldine.nouailles@charite.de)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health <https://orcid.org/0000-0003-1973-3119>

Emanuel Wyler

Berlin Institute for Medical Systems Biology (BIMSB) <https://orcid.org/0000-0002-9884-1806>

Peter Pennitz

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health

Dylan Postmus

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health <https://orcid.org/0000-0002-9551-0411>

Daria Vladimirova

Freie Universität Berlin

Julia Kazmierski

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health <https://orcid.org/0000-0002-7962-2165>

Fabian Pott

Charité - Universitätsmedizin Berlin <https://orcid.org/0000-0003-3700-1691>

Kristina Dietert

Freie Universität Berlin <https://orcid.org/0000-0002-5667-6750>

Michael Mülleider

Charite University Medicine

Vadim Farztdinov

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health

Benedikt Obermayer

Berlin Institute of Health <https://orcid.org/0000-0002-9116-630X>

Sandra-Maria Wienhold

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health

Sandro Andreotti

Freie Universität Berlin

Thomas Hoefler

Freie Universität Berlin <https://orcid.org/0000-0001-7486-5582>

Birgit Sawitzki

Institute of Medical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Inst

Christian Drosten

Charite - Universitätsmedizin Berlin <https://orcid.org/0000-0001-7923-0519>

Leif Sander

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health <https://orcid.org/0000-0002-0476-9947>

Norbert Suttorp

Charité Universitätsmedizin Berlin

Markus Ralser

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health

Dieter Beule

Berlin Institute of Health <https://orcid.org/0000-0002-3284-0632>

Achim Gruber

Freie Universität Berlin

Christine Goffinet

Charité - Universitätsmedizin Berlin <https://orcid.org/0000-0002-3959-004X>

Markus Landthaler

Max Delbrück Center for Molecular Medicine <https://orcid.org/0000-0002-1075-8734>

Jakob Trimpert

Freie Universitaet Berlin <https://orcid.org/0000-0003-1616-0810>

Martin Witzenrath

Charité Universitätsmedizin Berlin

Article

Keywords: COVID-19, immune response, disease severity

Posted Date: January 28th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-148392/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Nature Communications on August 11th, 2021. See the published version at <https://doi.org/10.1038/s41467-021-25030-7>.

Longitudinal omics in Syrian hamsters integrated with human data unravel cellular effector responses to moderate COVID-19

Geraldine Nouailles^{1,2†*}, Emanuel Wyler^{3†*}, Peter Pennitz¹, Dylan Postmus^{2,4}, Daria Vladimirova⁵, Julia Kazmierski^{2,4}, Fabian Pott^{2,4}, Kristina Dietert^{6,7}, Michael Muelleder⁸, Vadim Farztdinov⁸, Benedikt Obermayer⁹, Sandra-Maria Wienhold¹, Sandro Andreotti¹⁰, Thomas Hoefler⁵, Birgit Sawitzki¹¹, Christian Drosten⁴, Leif E. Sander¹², Norbert Suttorp¹², Markus Ralser¹³, Dieter Beule⁹, Achim D. Gruber⁶, Christine Goffinet^{2,4}, Markus Landthaler¹⁴, Jakob Trimper^{5‡*} and Martin Witzenrath^{1,12,15‡*}

† shared first authorship with equal contributions

‡ shared senior authorship with equal contributions

* Corresponding authors:

Correspondence to Geraldine Nouailles (geraldine.nouailles@charite.de), Emanuel Wyler (emanuel.wyler@mdc-berlin.de), Jakob Trimper (jakob.trimper@fu-berlin.de), Martin Witzenrath (martin.witzenrath@charite.de)

¹ Division of Pulmonary Inflammation, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

² Berlin Institute of Health (BIH), Berlin, Germany.

³ Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

⁴ Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health (BIH), Berlin, Germany.

⁵ Institute of Virology, Freie Universität Berlin, Berlin, Germany.

⁶ Institute of Veterinary Pathology, Freie Universität Berlin, Berlin, Germany.

⁷ Veterinary Centre for Resistance Research, Freie Universität Berlin, Berlin, Germany.

⁸ Core Facility - High-Throughput Mass Spectrometry, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health (BIH), Berlin, Germany.

⁹ Core Unit Bioinformatics, Berlin Institute of Health (BIH), Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) and Charité - Universitätsmedizin, Berlin, Germany.

¹⁰ Bioinformatics Solution Center, Freie Universität Berlin, Berlin, Germany.

¹¹ Institute of Medical Immunology. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

¹² Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

¹³ The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London, UK; Department of Biochemistry, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health (BIH), Berlin, Germany.

¹⁴ Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; IRI Life Sciences, Institute for Biology, Humboldt University Berlin, Berlin, Germany.

¹⁵ German Center for Lung Research (DZL), Berlin, Germany.

Abstract

In COVID-19, immune responses are key in determining disease severity. However, cellular mechanisms at the onset of inflammatory lung injury in SARS-CoV-2 infection, particularly involving endothelial cells, remain ill-defined. Using Syrian hamsters as model for moderate COVID-19, we conducted a detailed longitudinal analysis of systemic and pulmonary cellular responses, and corroborated it with datasets from COVID-19 patients. Monocyte-derived macrophages in lungs exerted the earliest and strongest transcriptional response to infection, including induction of pro-inflammatory genes, while epithelial cells showed weak activation. Without evidence for productive infection, endothelial cells reacted, depending on cell subtypes, by strong and early expression of anti-viral, pro-inflammatory, and T cell recruiting genes. Recruitment of cytotoxic T cells as well as emergence of IgM

antibodies preceded viral clearance at day 5 post infection. Investigating SARS-CoV-2 infected Syrian hamsters can thus identify cell type-specific effector functions, provide detailed insights into pathomechanisms of COVID-19, and inform therapeutic strategies.

Introduction

The enduring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has emphasized the urgent need for experimental models to rapidly identify pathomechanisms and therapeutic targets of Corona Virus Disease 2019 (COVID-19).

COVID-19 causes a wide range of disease manifestations, spanning from asymptomatic infections to acute respiratory distress syndrome (ARDS) and fatal multi-organ dysfunction ¹. Disease severity is influenced by age, sex and specific comorbidities, making it evident that host-specific factors influence the course of the disease and require further investigation. While blood of COVID-19 patients is accessible to detailed longitudinal investigation irrespective of disease severity, and bronchoalveolar lavage (BAL) can be safely performed in intubated patients, pulmonary tissue responses remain inaccessible in mild and moderate COVID-19 courses, since lung tissue is only available upon autopsy from patients with fatal disease. Hence, experimental models of COVID-19 are needed, which reflect the complexity of human responses to SARS-CoV-2 infections, including the spatiotemporal dynamics of airway and alveolar infection, local pulmonary immune responses, the activation of systemic inflammatory, complement and coagulation cascades, the impairment of endothelial barrier function, and also mechanisms of resilience, resolution and repair.

The hamster family (Cricetinae) is of particular interest for experimental modelling of COVID-19, as we and others have observed that animals without genetic modifications can be infected with SARS-CoV-2 and develop phenotypes ranging from mild to lethal COVID-19, depending on age and species ²⁻⁶. Notably, immune cell influx into the lungs, bronchointerstitial pneumonia and diffuse alveolar damage in hamsters bear resemblance to COVID-19 in human patients ⁷⁻⁹.

Since its initial description as animal model for SARS-CoV ¹⁰, the Syrian hamster has been used to study different aspects of SARS-CoV and Middle East Respiratory Syndrome (MERS) coronavirus infection ¹¹⁻¹³. Consequently, it now serves as a

versatile non-transgenic rodent model to study SARS-CoV-2 infection and therapeutic interventions such as antiviral treatments, immunomodulatory therapies and vaccines^{3,7,14}. The disease observed in hamster species primarily affects the lower respiratory tract, which more closely resembles the common courses of human disease as opposed to clinically severely affected transgenic mice, in many of which infection of the central nervous system (CNS) is the predominant manifestation of the disease^{15,16}.

Despite the advantages of hamster models for investigating COVID-19 pathogenesis, unavailability of molecular tools and reagents for hamsters limits investigations of immuno-pathomechanisms, leaving unanswered how closely SARS-CoV-2 evoked disease in hamsters models human COVID-19. We therefore in-depth evaluated SARS-CoV-2-infected Syrian hamsters (*Mesocricetus auratus*), elucidating the innate and adaptive steps of immunity and pathogenesis by pairing single-cell RNA sequencing (scRNA-Seq) data from lung cells and white blood cells (WBC), histopathology and quantitative proteomics analysis of lungs and blood following nasal SARS-CoV-2-infection of *Mesocricetus auratus*. We compared our findings with own data from scRNA-Seq and proteomics analyses from human biosamples of COVID-19 patients. This enabled in-depth investigations on central COVID-19 pathomechanisms in compartments inaccessible in humans, particularly in moderate disease.

Results

SARS-CoV-2 induces self-resolving moderate pneumonia and robust pulmonary immune cell recruitment in Syrian hamsters

After infection with SARS-CoV-2 (Figure S1), clinical disease manifested in Syrian hamsters with moderate transient weight loss analogous to previous reports^{(2,3,6}, Figure S2a). High viral loads were detected in respiratory tracts at 2, 3 and 5 days post infection (dpi). At 14 dpi, only minimal viral RNA load remained, and no replication competent virus was detected in the respiratory tract (Figure S2b – d). Lack of viral RNA in the blood of all animals suggested absence of systemic infection (data not shown).

Similar to previous observations^{2,9}, histopathology identified necrosuppurative bronchitis and bronchointerstitial pneumonia at 2 and 3 dpi, characterized by intrabronchial and intraalveolar infiltration by neutrophils and macrophages as well as

Figure 1

Figure 1: Single-cell dynamics in lungs and blood of SARS-CoV-2 infected Syrian hamsters

(a), UMAP plot of identified cell populations in Syrian hamster lungs. (b), Cell count of isolated cells per lung lobe over time (2, 3, 5 and 14 dpi) and control group (naïve, “d0”). (c), Count of hematopoietic cells per lung lobe in naïve hamsters and over time pi. (d), Changes in cellular density of lung cells in UMAP projection. Coloration indicates log2 fold change between control group and 5 dpi. (e), Percentage of hematopoietic cells per lung lobe in naïve hamsters and over time pi. (f), UMAP plot of identified cell populations in blood samples. (g), Cell count of isolated cells per mL blood in naïve hamsters and over time pi. (h), Percentage of identified cell populations in blood samples over time pi and naïve animals. (i), Neutrophil–lymphocyte ratio in blood samples over time pi and naïve animals. (a, d and f), Clusters defined by Louvain clustering, $n = 3$ per time point. (b, c, e, g, h and i), Data display means $\pm$ SD. $n = 3$ per time point. Ordinary one-way ANOVA, Sidak’s multiple comparisons test versus corresponding 0 dpi (naïve). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$

severe, diffuse alveolar damage. Numbers and density of infiltrating immune cells, hyperplasia of bronchial and alveolar epithelial cells as well as alveolar and interstitial edema and endothelialitis peaked at 5 dpi. By 14 dpi, cellular influx into alveolar spaces was largely resolved, with fewer neutrophils, macrophages and lymphocytes observed within the interalveolar septa, while marked hyperplasia of alveolar epithelial cells remained (Figure S2e – n). Again, consistent with previous reports^{2,9} no evidence of thrombotic events were observed.

To obtain higher resolution of pulmonary responses, we performed scRNA-Seq. Cell type clusters detected in lungs corresponding to leukocyte-subset-signatures included alveolar, interstitial, and monocytic macrophages, *Trem14*⁺-monocytes, neutrophils, dendritic cells, B, T, and natural killer (NK) cells. We further identified resident cell types, including alveolar epithelial cells type 1 (AT1) and 2 (AT2), ciliated epithelial, endothelial, and smooth muscle cells, and fibroblasts (Figure 1a, S3a). By integrating scRNA-Seq-derived cell frequencies with manually counted cell numbers over time, we mapped dynamics of infection-induced pulmonary leukocyte recruitment compared to uninfected animals (Figure 1b, c). Neutrophils were first immune cells recruited to lungs (peak at 2 dpi), closely followed by an influx of monocyte-derived macrophages (peak at 5 dpi). NK and T lymphocyte recruitment to lungs was first detected at 5 dpi and peaked at day 14 (Figure 1c). Peak of lung inflammation on 5 dpi (Figure S2l) coincided with the highest proportion of inflammatory macrophages (monocytic macrophage cluster) and proliferating cytotoxic cells (T/ NK cell cluster) among lung cells (Figure S3b).

Notably, despite pronounced neutrophilic bronchitis (Figure S2g), overall neutrophil frequencies remained low. In line with histopathology, the peak of neutrophil recruitment was at 2 dpi, when neutrophil proportions presented ~3 % of lung cells (Figure 1e). In contrast, monocytic macrophages population at day 5 peaked at ~25 % of lung cells (Figure 1d, e, S3b). Relative numbers of pulmonary tissue cell subsets fluctuated mildly, declining proportionally as inflammatory cell influx rose (Figure S3c, d). At 14 dpi, increased numbers of AT2 matched histopathology observations of epithelial hyperplasia, indicating tissue repair (Figure S2i, k, S3c).

Analogously, we analyzed scRNA-Seq data from WBC populations to study systemic responses evoked by pulmonary SARS-CoV-2 infection. Detected cell populations included neutrophils, monocytes, dendritic, NK, B and T cells and various subpopulations thereof (Figure 1f, S3e). Infected hamsters displayed significant

leukopenia at 3 and 5 dpi. By 14 dpi this trend was inverted and peripheral blood leukocyte numbers were significantly higher than in naïve animals (Figure 1g, S3f). Increased proportions of neutrophils were found at 2 dpi and increasing proportions of T cells at 14 dpi (Figure 1h, S3b). Notably, calculated neutrophil–lymphocyte ratios only transiently increased at 2 dpi to a minor extent, matching observations in humans with non-severe as opposed to severe COVID-19^{17,18} (Figure 1i). Overall, scRNA-Seq cell profiling defined kinetics of immune cell trafficking in greater detail.

Bulk transcriptomics, proteomics and single-cell RNA sequencing reveal activation of anti-SARS-CoV-2 pro-inflammatory immunity in hamsters

After evaluating immune cell dynamics, we performed bulk RNA-sequencing of lungs and blood and matched proteomics of lungs and serum to gain insights into alterations of SARS-CoV-2-induced immune responses.

Gene ontology (GO) enrichment analysis of the infection-triggered most differentially expressed genes in lungs and blood provided expected GO terms such as *defense response to virus*, *innate immune response*, and *cell activation* (Figure S4a, b). Pulmonary gene sets related to *type 1 interferon (IFN) signaling* correlated with presence of viral RNA, thus vanished by 14 dpi. Similarly, pulmonary gene sets related to *response to interferon-gamma (Ifng)* were highest at 5 dpi (Figure S4c). In blood, *type 1 IFN signaling* and *response to IFN- γ* gene sets were highest at 2 and 3 dpi (Figure S4d), perhaps reflecting recruitment of specific cells from blood to lungs. Overall, bulk RNA-seq identified an anti-viral immune response that was effectively resolved when the virus was cleared.

The proteome host response was in line with the sequencing data, with differentially expressed serum proteins peaking at 3 dpi and lung proteins at 5 dpi (Figure S4e). Agreement between bulk RNA sequencing and proteomics was consistent in lungs at 5 dpi ($r = 0.9$) (Figure S4f). Functional terms connected with immune response, such as innate and adaptive immunity, activation of complement system, humoral immune response and regulation of immune system processes were most enriched (Figure 2a). In lungs, response to interferon-beta peaked at 3 dpi and stayed high until 5 dpi (Figure 2a). Most processes were resolved by 14 dpi.

We next aimed at comparing our data to published datasets from COVID-19 patients. In hamster serum, 37 differentially expressed proteins were identified ($\alpha = 0.01$, providing FDR below 6 %), 17 compared to control and 31 proteins compared to 14

Figure 2

Figure 2: Proteomics analysis recapitulates transcriptomics and human COVID-19 patient data

(a), Temporal evolution of gene ontology/biological process terms connected with immune system response in lung tissue (left part) and in serum fluid (right part), for the indicated time points compared to samples from uninfected animals. Enriched terms were filtered for terms mentioning “immune”, “interferon”, “neutrophil”, “T cell” and “B cell”. Size of dots correspond to the inverse of the false discovery rate. (b), Expression values for differentially regulated proteins in hamster serum (control 3 dpi, p value < 0.01) and lung (control 5 dpi, p value < 0.01) that correlate with disease severity in human plasma. Controls from different days are plotted together. The thick line represents median of all values, lower and upper hinges correspond to medians of lower and upper half of set, respectively. Whiskers extend to a maximum of 1.5 times distance between first and third quartile. All values are shown. (c) Expression values for the differentially expressed proteins Lgals3 and Lgals3bp (only detected in lung samples).

dpi when most effects are resolved. Of 31 proteins, 20 have been reported in human COVID-19 studies, 7 (Actg1, Apoa1, Apoc1, Gsn, Hp, Itih3, Lbp) of which correlate with disease severity¹⁹, all showing the same direction (Figure S4g). In hamster lungs, at peak response (5 dpi) we identified 150 differentially expressed proteins. 13 differentially expressed proteins have been reported to be regulated in human plasma²⁰ with 9 showing the same trend (Table S2). Of these, 6 proteins (C4b, Hp, Hpx, Igkm, Igkv7-33, Itih3) are also changed in hamster serum (Figure 2b). Although a comparison to moderate disease in human lung tissue is not possible, 22 proteins are reported to be regulated in human BAL fluid of critically ill patients²¹. The few proteins showing opposite regulation to COVID-19 patients were confirmed by bulk sequencing. Five out of 7 conflicting responses, namely C4b, Hpx, Rbp4, Cfd, and Agt in hamster serum compared to human plasma as well as 8 out of 12 for hamster lung tissue compared to human BAL were confirmed.

Next, we refined transcriptome analyses with scRNA-Seq and related identified bulk GO terms to cell types, concentrating on inflammatory mediators (Figure 3). Indeed, various pro-inflammatory chemokines were expressed by lung cells and showed distinct cellular and temporal expression patterns. Classical pro-inflammatory cytokines, e.g. *Il1a* and *Il1b* transcripts were elevated only early at 2 and 3 dpi in alveolar and monocytic macrophages, and alveolar macrophages and *Trem14*⁺ monocytes, respectively. By 5 dpi, AT2 cells showed a unique range of upregulated inflammatory mediators such as *Cxcl17*, *Lipopolysaccharide Binding Protein (Lbp)*, *fibrinogen gamma gene (Fgg)*, and *clusterin (Clu)*. *Galectin 3-binding protein (Lgals3bp)* gene stood out as being upregulated in many cell types from 2 dpi to 5 dpi (Figure 3). Notably, we likewise measured increased levels of Lgals3bp protein in lungs (Figure 2c), which was shown to be regulated also in plasma of COVID-19 patients and correlated with severity¹⁹.

Taken together, we identified clear changes in transcriptome, proteome and pro-inflammatory signatures on single-cell level in response to SARS-CoV-2 infection, displaying highly active immune responses that to large extents were also described in COVID-19 patients.

Figure 3

Figure 3: Induction of inflammatory mediators are strongest and earliest in myeloid cells

Dotplots of differentially expressed cytokines and inflammatory mediators in lungs. Shown are genes that display a significant absolute log2-transformed fold change of at least one in at least one comparison, and are grouped into four categories indicated on the left. Coloration and point size indicate log2-transformed fold changes and P values, respectively, of genes at 2 dpi relative to control groups (naïve). Adjusted P values were calculated by DEseq2 using Benjamini-Hochberg corrections of Wald test p values. Genes are ordered by unsupervised clustering, cell type as in Figure 1.

Migratory myeloid cells dominate pulmonary transcriptional response to SARS-CoV-2 infection in Syrian hamsters and COVID-19 patients

To pinpoint individual roles of identified cells in anti-SARS-CoV-2 immunity, we analyzed the 15 - 20 most differently expressed genes in each cell subset. In early stages of infection at 2 dpi, robust, local transcriptome changes were observed primarily in lung monocytic and interstitial macrophages, neutrophils and endothelial cells, whereas AT1 and AT2 epithelial cells and alveolar macrophages showed comparably little change in mRNA expression (Figure 4a). A common set of anti-viral effector genes was found upregulated in many cell types²². These include e.g. *interferon-stimulated gene 15 (Isg15)*, *MX dynamin like GTPase (Mx)1*, *Mx2*, *Interferon-induced protein with tetratricopeptide repeats 3 (Ifit3)*, and *Sp100*, as well as transcription factors, such as *Interferon regulatory factor (Irf) 7* and *Irf9* (Figure 4a, Figure S5a). Blood transcriptome analysis recapitulated this early transcriptional activity at 2 dpi (Figure 4b, Figure S5b), but declined by 5 dpi, whereas the signature persisted in the lungs until 14 dpi (Figure S5a, b).

Genes that differed most between classical blood monocytes and their counterparts in lungs encoded chemokines and activation markers, including *CXC chemokine ligand 10 (Cxcl10)*, *Slamf9*, *Il18bp*, *Ifitm2*, *Ccl8*, *Ccl4* and *Ccl5* (Figure 4c, Figure S5c), indicating that activation and acquisition of effector function occurred in lungs. Although AT2 cells are a main target of SARS-CoV-2 in lungs²³, they displayed weaker and later transcriptional changes upon infection compared to monocytic macrophages (Figure 4a, d, S5a, d). Notably, at 14 dpi differential transcriptional responses related to defense resolved in blood and lung cells. Instead, we observed upregulation of cell cycle proliferation genes in AT2 cells including *Marker of Proliferation Ki-67 (Mki67)*, *Ubiquitin-conjugating enzyme E2 C (Ube2c)*, *Aurora B kinase (Aurkb)*, and *Stathmin (Stmn1)* (Figure S5a). This transcriptome profile indicated initiation of a repair program by AT2 cells, proliferating to replace damaged AT1 cells²⁴. Finally, we put our hamster lung scRNA-Seq data in context with BAL scRNA-Seq data from patients with moderate-to-severe COVID-19²⁵ and healthy controls²⁶. As in hamster data, we observed stronger transcriptional responses in macrophages compared to epithelial cells (Figure S5e). Furthermore, the upregulated gene program containing e. g. *CXCL10*, *CCL2* or *CCL8* was substantially overlapping (Figure S5f).

Figure 4

Figure 4: Transcriptional response to SARS-CoV-2 infection is strong in myeloid and moderate in epithelial cells (a, b), Dotplot of differentially expressed genes in lungs (a) and blood (b). Shown are genes that are in at least one cell type among the top 4 most changing genes as ranked by adjusted p value. Example: top 4 most changing genes in alveolar macrophages are *Ybx3*, *Rps15*, *Rps10*, and *Uba52*. Coloration and point size indicate log2-transformed fold changes and p values, respectively, of genes at 2 dpi relative to control groups (naïve). Adjusted p values were calculated by DEseq2 using Benjamini-Hochberg corrections of Wald test p values. Cell types and genes are ordered by unsupervised clustering. (c), Top, fraction of monocytic macrophages expressing *Cxcl10* in blood and lungs from naïve animals and 2 dpi. Bottom, boxplots of *Cxcl10* gene expression values of cells positive for *Cxcl10* expression. Significance levels were calculated using generalized linear mixed-effects models for bar plot and a Wilcoxon rank sum test on all cells (i.e. not only the ones expressing the gene) for boxplots. * means p value 0.05-0.01, ** means p value 0.01-0.0001, *** means p value smaller 0.0001. See materials and methods for details. (d), As in (c), but only in lungs, all time points and both alveolar epithelial cells type 2 (AT2) and monocytic macrophages. Displayed are values for *Isg15* (left) and *Cxcl10* (right). For all bar plots, data display means $\pm$ SD, n = 3 per time point. For all boxplots, lower and upper hinges correspond to first and third quartiles. Whiskers extend to a maximum of 1.5 times the distance between first and third quartile. Outliers beyond are marked by single dots.

To test whether hamster tissue responses are representative of infected human epithelial cells, we next referred to our scRNA-Seq dataset derived from nasopharyngeal swabs of 19 COVID-19 patients and 5 healthy controls²⁷. Here again, human and hamster epithelial cells derived from infected individuals and animals, respectively, showed a similar, moderate induction of most inflammatory mediators (Figure S6a, b). As notable difference, strong induction of neutrophil-recruiting chemokines targeting CXC chemokine receptor (CXCR) 2, such as *CXCL1*, *CXCL3*, *CXCL6* and *CXCL8*, were found only in human basal and secretory cells with severe COVID-19 but were absent in moderately-ill Syrian hamsters (Figure S6a, Figure 3). Aside from the epithelial inductions of neutrophil-attractant transcripts unique to severe COVID-19, SARS-CoV-2 infected hamsters and patients displayed strikingly similar pro-inflammatory immune profiles specifically in migratory myeloid cells.

Early activation of TLR/NF-κB-dependent transcription of pro-inflammatory cytokines in monocytic macrophages by SARS-CoV-2 infection

Next, we asked whether observed cellular transcriptional responses to SARS-CoV-2 infection were influenced by presence of virus in individual cell types. First, we determined fractions of cells expressing SARS-CoV-2 entry receptors, *Angiotensin-converting enzyme 2 (Ace2)* and *transmembrane serine protease 2 (Tmprss2)*, putative alternative receptors, *Basigin (Bsg)* and *Furin*, and cofactors, such as neuropilins (*Nrp1*), and heparan sulfate (*exostosin-1, Ext1*)²⁸⁻³⁰ in hamster lungs (Figure 5a, Table S3). Ciliated epithelial cells most frequently expressed *Ace2* (~4 – 22 %), as did a smaller proportion of AT2 cells (~3 – 5 %) (Table S3). By in situ hybridization, we visualized SARS-CoV-2 RNA in bronchial epithelial cells (Figure 5b), and AT1 (Figure 5c, arrowhead) and AT2 (Figure 5c, arrow) cells, whereas endothelial cells were consistently devoid of virus (Figure 5b, hash). Importantly, viral RNA was detected in high numbers of intrabronchial and intraalveolar macrophages (Figure 5d, arrows) at early time points. A fraction of macrophages contained high loads of virus without cell debris, pointing towards uptake of cell-free virus (Figure 5d, inset). For comparison, a control staining section of alveoli is shown (Figure 5e).

ScRNA-Seq data suggested that most viral RNA content was found in monocytic macrophages, and not in epithelial cells (Figure 5f, Table S3). For epithelial and endothelial cells, frequencies of virus-positive cells were highest at 3 dpi, declining by

Figure 5: Virus RNA in monocytic macrophages leads to dose-dependent activation of pro-inflammatory cytokines by TLR signaling

(a), Feature plots of entry factor expression in UMAP projection. Coloration indicates expression values of indicated genes. (b-e), Detection of viral RNA by in situ-hybridization. Labeled are supposed endothelium (b, hash), bronchial epithelial cells (b, arrowhead), AT1 (c, arrowhead) and AT2 (c, arrow). (d, inset), macrophages containing viral RNA and cell debris (arrowhead), and an example of high levels of viral RNA without cell debris in the inset (arrow). For (b-e), red signals viral RNA and blue hemalaun counterstain. Time points: (b-c) from 2 dpi, (d) from 3 dpi, (e) staining control. Bars: (b, d, e) = 50 μ m, (c) = 100 μ m, Inset in (c) = 20 μ m. (f), Cells in the UMAP projection are colored by amount of viral RNA (log10 transformed percentage of viral RNA per cell), along with overview of identified cell types in lungs. (g), Dotplot of cytokine expression in monocytic macrophages containing viral RNA compared to those without viral RNA. Coloration and point size indicate log2 fold change and P value for each time point 2, 3 and 5 dpi. (h, i), Box- and barplots of *Isg15* (h) and *Cxcl10* (i) gene expression in AT2 and monocytic macrophages along, comparing cells containing viral RNA to those without for 2, 3, and 5 dpi. Barplot shows percentage of cells positive for respective gene, with mean $\pm$ SD, n = 3. Boxplots show gene expression levels in cells positive for respective gene. (j), Box- and barplots of *Cxcl10* in monocytic macrophages and fraction of *Cxcl10* positive cells for each time point pi and naïve animals, with cells grouped by increasing virus levels for 2, 3, and 5 dpi. (e and f), for barplots, data display means $\pm$ SD. Significance levels calculated using generalized linear mixed-effects models for barplot and a wilcoxon rank sum test on all cells (i.e. not only the ones expressing the gene) for boxplots. * means p value 0.05-0.01, ** means p value 0.01-0.0001, *** means p value smaller 0.0001.

5 dpi to become absent at 14 dpi, indicating removal of virus-containing cells (Table S3). In contrast, alveolar macrophages showed highest viral loads at 5 dpi (~25 %), paralleling decline of virus-positive tissue cells, thus pointing towards potential increase in phagocytic activities (Table S3).

To further investigate how cell-specific gene expression is modulated by cell-associated viral RNA, we tested the correlation between gene expression and viral load in monocytic macrophages. We first compared gene expression levels in monocytic macrophages that did (vRNA⁺), or did not (vRNA⁻) contain viral RNA (Figure 5g, S7a). This revealed a set of genes that only at early disease stages (2 dpi, 3 dpi), were present at higher levels in vRNA⁺ monocytic macrophages (Figure S7a). Gene ontology and KEGG pathway analysis showed that this gene set was enriched for Toll-like receptor (TLR) signaling (Figure S7b). Specifically, this gene set contained a range of pro-inflammatory cytokines such as *Cxcl10* or *Ccl2* (Figure 5g), which are activated by the NF-kB pathway downstream of TLRs³¹. On the other side, expression levels of NF-kB independent ISGs such as *Isg15* or *Mx2*, induced by interferons or cytosolic RNA sensors³², were only slightly more elevated in vRNA⁺ compared to vRNA⁻ monocytic macrophages (Figure 5g). Therefore, we investigated representative genes, *Isg15* and *Cxcl10*, in more detail (Figure 5h, i). *Isg15* expression was found in about 2/3 of AT2 and all monocytic macrophages at 2 dpi. *Isg15* levels in gene-positive cells were higher at 2 dpi in vRNA⁺ AT2 cells and at 2, 3, and 5 dpi vRNA⁺ monocytic macrophages compared to corresponding vRNA⁻ cells (Figure 5h). In comparison, *Cxcl10* was nearly absent in AT2 cells at 2 dpi and 3 dpi. *Cxcl10*-positive cell fractions and gene expression levels were significantly higher in vRNA⁺ monocytic macrophages compared to vRNA⁻ cells at 2, 3 and 5 dpi (Figure 5i). We further analyzed dose-dependency of this transcriptional response to virus in monocytic macrophages. Cells were binned in three groups of equal size with increasing content of viral RNA. We found that at earlier time points (2 and 3 dpi), but not at 5 dpi, cells with higher amounts of viral RNA-signal, also expressed more *Cxcl10* (Figure 5j).

Overall, this indicated that sensing of viral RNA activated monocytic macrophages in a dose-dependent manner, leading to increase of NF-kB-regulated pro-inflammatory chemokines. At 5 dpi, broad inflammation likely masked direct viral RNA-triggered responses by activating expression of pro-inflammatory genes in vRNA⁺ and vRNA⁻

cells equally. In contrast, AT2 cells showed less activation of both NF-κB-dependent and -independent transcriptional responses as compared to monocytic macrophages.

Endothelial cells participate in anti-viral and pro-inflammatory responses

Having observed vast similarities of human and Syrian hamster immune responses in moderate SARS-CoV-2 infection on transcriptomic and proteomic levels, we next turned our attention to dissection of molecular mechanisms in lung tissue compartments that have so far not been assessed longitudinally in moderate COVID-19 patients, since invasive tissue sampling is hardly possible.

Endothelial cells likely participate in COVID-19 pathogenesis^{33,34}, but little is known about dynamics of their responses to inflammation *in vivo*. Subclustering of cells of endothelial origin identified endothelial cells of lymphatic and bronchial vasculature, pulmonary arteries, capillaries and veins with unique features (Figure 6a, Figure S8a, b). Interestingly, bronchial endothelial cells, pulmonary artery and capillary endothelial cells all displayed strong and early anti-viral gene expression profiles at 2 dpi (Figure 6b). Pulmonary arterial endothelial cells responded most rapidly to infection, with high expression of *Cxcl10*, *Tnfrsf10*, and *Ccl7* by 2 dpi (Figure 6c). Responses of bronchial vasculature, pulmonary capillary and pulmonary vein endothelial cells were similar but delayed, peaking at 5 dpi. In addition to distinct temporal dynamics of endothelial activation in different tissues, we observed a spatial regulation of expression of monocyte and effector T cells attractants. Pulmonary artery and vein endothelial cells preferentially transcribed *Ccl7*, a chemoattractant binding multiple CC receptors, including CCR1-3, CCR5, and CCR10³⁵. Pulmonary capillary endothelial cells, however, preferentially expressed the pleiotropic *Ccl8*, binding at least CCR2, CCR3 and CCR5³⁶, while bronchial vasculature endothelial cells were characterized by *Ccl2* (Figure 6c). ICAM-1 and VCAM-1 upregulation, occurs following inflammatory stimuli to allow for leukocyte transmigration³⁷, and was highest in bronchial endothelial cells and pulmonary artery cells at 5 dpi, corresponding to influx of T cells (Figure 6c). Overall lung endothelial cells shared an anti-viral gene profile but revealed distinct patterns of chemokines targeting primarily monocytes and Th1 cells. Unlike cells of epithelial origin, endothelial cells failed to show evidence of proliferation and cell cycle activity that could have indicated their participation in tissue repair processes during the study period (*DNA topoisomerase 2-alpha* (*Top2a*), *Mki67*, *Ube2c*) (Figure 6c).

Figure 6

Type 1 effector T cells are efficiently recruited to lungs in SARS-CoV2 infection

Our initial cellular analysis of scRNA-Seq data from lung samples had grouped T and NK cells in one set of connected clusters, and we had observed their significant increase in lungs at 5 and 14 dpi (Figure 1). We hypothesized that cytotoxic immunity might be linked to viral clearance observed at 5 dpi, and elimination by 14 dpi (Figure S2). Therefore, we subclustered NK and T cells to identify 4 subpopulations based on *Cd3e*, *Cd4*, *Cd8a* and *Natural Killer Cell Granule Protein 7 (Nkg7)* gene expression (Figure 7a, S9a), CD4⁺ T cells (*Cd3e*⁺*Cd4*⁺), CD8⁺ T cells (*Cd3e*⁺*Cd8a*⁺), NK cells (*Cd3e*⁺*Nkg7*⁺) and innate lymphoid-(ILC) like cells (*Cd3e*⁺*Cd4*⁺*Cd8a*⁺*Nkg7*⁺). CD4⁺ T, CD8⁺ T and NK cell numbers increased with infection time and peaked at 5 dpi (Figure 7b). SARS-CoV-2 infection initiated type 1 immunity and cytotoxic effector mechanisms in lungs (Figure 7c, S9b). The fraction of NK cells expressing interferon gamma (*Ifng*) increased significantly at 2 dpi and peaked at 3 dpi (Figure 7d, left). In contrast, *Ifng*⁺ effector T cells (*Ifng*⁺ CD4⁺ and CD8⁺ T cells) peaked at 5 dpi (Figure 7d, right). By 14 dpi, both *Ifng*⁺ NK and T cell responses had declined to naïve levels (Figure 7d).

NK cells and CD8⁺ T cells expressed high levels of cytotoxic genes, but upregulation of *Gzma* was highest in CD4⁺ T cells (Figure 7c, S9b). Cytotoxic effector function of T cells was evident, 60 % of all CD4⁺ T and 70 % of all CD8⁺ T cells expressed *Gzma* at 5 dpi (Figure 7e). Furthermore, we detected “cells” carrying both a specific cell type marker (for AT1 / AT2 / endothelial cells, or monocytic macrophages), and simultaneously the cytotoxic cell marker *Gzma*. These possible doublets were absent in naïve animals and appeared particularly and reproducibly for endothelial and AT1 cells at the peak of effector T cell recruitment 5 dpi (Figure 7f), indicating possibly either killer-target interaction or T cell transmigration. The latter notion was supported by the strong immigration of lymphocytes in the endothelium observed in histopathology (Figure 7g).

Induction of high-affinity neutralizing antibodies is the primary aim of most vaccination strategies against viruses. In the here described primary infection with SARS-CoV-2, neutralizing antibodies were evident by 5 dpi and declined mildly until 14 dpi (Figure 7h). Matching course of μ heavy chain protein levels measured by proteomics (Ighm, Figure 2b). Peak of T cells and neutralizing IgM antibodies corresponded with vanishing virus, indicating successful adaptive effector programs.

Figure 7

Figure 7: Syrian hamsters exhibit a strong cytotoxic T/NK cell response at day 5 post infection

(a), UMAP plot of lung T/NK cell subclustering indicating cell subpopulations. (b), Count of lung T cell subpopulations and NK cells per lung lobe. (c), Dotplot of master regulators of T cell differentiation and effector genes. Coloration and point size indicate log2 fold change and p value, respectively. (d), Fraction of *Ifng*⁺ cells in CD4⁺ T, CD8⁺ T and NK cells at 2, 3, 5 and 14 dpi and naive. (e), Fraction of *Gzma*⁺ cells in CD8⁺ T cells at 2, 3, 5 and 14 dpi and naive. (f), Fraction of AT2 cells, monocyte macrophages, endothelial cells and AT1 cells containing both at least one cell type marker gene (AT2: *Sftpa1*, *Sftpc* – monocyte macrophages: *Fcn1*, *Saa3* – endothelial cells: *Cldn5*, *Plvap* – AT1: *Ager*, *Aqp5*) together with *Gzma*. Data display means $\pm$ SD, n = 3 per time point. (g), Histopathology of blood vessels at different time points, bar: 50 μ m. (h) Serum neutralization titers of SARS-CoV-2 infected hamsters at 5 and 14 dpi. Serum titers of naive, 2 and 3 dpi did not neutralize up to detection limit 1:4 (dotted line). Data display n = 3 with mean per time point.

Discussion

Detailed understanding of COVID-19 pathophysiology is imperative for the development of therapies to reduce numbers of patients developing lung injury. Notably, recent patient-centered research on COVID-19 was compromised by three blind spots: (i) Biomaterial is usually sampled after hospital admission, therefore the early phase of infection and host response has rarely been investigated. (ii) the BAL procedure to access the alveolar compartment is too dangerous for non-intubated patients with COVID-19 pneumonia, so that alveolar host responses can hardly be investigated in mild and moderate COVID-19. (iii) Lung tissue can exclusively be harvested after death in COVID-19 patients, precluding from investigations of non-myeloid alveolar or endothelial host responses in early disease, and enabling for analysis of later disease stadium only in case of fatal outcome. Thus, we performed in-depth analysis of the full course of moderate, self-limited disease that develops in SARS-CoV-2 infected Syrian hamsters. In this model, lungs are fully accessible, providing for detailed analysis of myeloid and non-myeloid compartments including vascular endothelium. Yet, while the immune response is qualitatively similar between human and hamsters in central aspects, the viral dose applied in experimental infections is likely to be higher than in natural aerosol infection. Consequently, infection kinetics, viral decay rate and immune responses are accelerated^{38,39}. In line, we observed the pulmonary peak of viral load, inflammation and cellular response between 3 and 5 dpi, whereas at 14 dpi the infection was resolved and mechanisms of tissue regeneration were induced. This course of disease confirms observations in other animal models including non-human primates. Syrian hamsters developed rapid, but moderate, neutrophil recruitment predominantly to bronchi and lung parenchyma, which resolved by 3 dpi. We also observed little of the typical neutrophil-dependent alveolar damage. Although single-cell RNA-sequencing analysis likely underestimates the numbers of this fragile cell type⁴⁰, these findings suggest a minor role for neutrophils. Nonetheless, the neutrophil response is noteworthy, as many other respiratory viruses, e.g. Influenza A Virus and MERS Virus, initiate little or no neutrophil trafficking in rodents⁴¹. In fact, blood N/L ratios in COVID-19 patients were reported as markers for disease severity, and neutrophil extracellular traps as well as reactive oxygen species are suspected to contribute to adverse vascular events^{42,43}. Confirming our classification of

hamsters as a moderate disease model, N/L ratios were only mildly elevated at 2 dpi, and gene signatures of dysfunctional immunosuppressive neutrophils were observed in severe COVID-19 patients⁴⁴, but not in Syrian hamsters.

In line with COVID-19 patient reports, alveolar macrophage numbers did not decrease in moderate disease settings²⁵, and monocytic macrophages were the largest cell population recruited to the lungs, with notable recruitment from 2 dpi on, and peak presence at 5 dpi^{27,44}. Monocyte trafficking to lungs was initiated by local expression of CCR2 ligands, and endogenous chemokine expression served as a feedforward loop. Consequently, macrophages were the predominant inflammatory cell type in alveolar spaces as identified by histopathology. Moreover, macrophages presented the earliest and strongest transcriptional response to the infection, primarily responding to intracellular viral RNA with pro-inflammatory cytokines such as CXCL10, CCL2 and others. Notably, the monocytic macrophage pro-inflammatory expression profile was rather productive than dysregulated as it tended more towards effector T cell recruiting chemokines targeting CXCR3 and CCR5, and less towards pro-inflammatory cytokine expression. This matches observations on moderate versus severe courses of COVID-19 in patients and stands in contrast to findings in animal models with severe disease progression such as K18-hACE2 mice^{16,25}. It seems unlikely that intracellular viral RNA found in macrophages is the result of active infection of these cells, as they have been demonstrated to be largely resistant to infection *ex vivo*⁴⁵. scRNA-Seq data obtained from African green monkeys infected with SARS-CoV-2 likewise did not support virus replication in macrophages⁴⁶. Instead, virus uptake may derive from complement receptor and Fc receptor-mediated phagocytosis of complement and antibody-labeled virus, as suggested by neutralizing antibody titers at 5 dpi⁴⁷. Further, we observed early increase in complement factors and IgM mu chain by proteomics analysis in lung tissue. Taken together, the Syrian hamster model endorses the hypothesis that monocyte-derived macrophages are a primary source of the strong pro-inflammatory response observed in COVID-19, yet highlights that their presence not necessarily results in fatal outcome⁴⁸.

Presumably, in the lung SARS-CoV-2 primarily infects AT2 cells²³. Of note, only few of them were infected and they reacted with only marginal transcriptional responses, which is probably explained by the recent observation in human lungs that less than 10% of AT2 cells express the crucial entry receptor ACE2⁴⁵. Moreover,

coronaviruses are endowed with a multitude of mechanisms that block immunological cascades downstream of interferon signaling and cytoplasmic RNA sensing⁴⁹. Only a small subset of *in vitro* highly infected cells express pro-inflammatory genes^{50,51}. Thus, despite being the primary target for viral replication, epithelial cells were not accountable for early systemic propagation of anti-viral or pro-inflammatory signatures.

Endothelial barrier dysfunction, resulting from endothelial cell stress or death, evokes lung edema and thus contributes to lung failure in severe COVID-19^{34,52-54}. However, mechanisms driving endothelial barrier failure in COVID-19 are not well understood, as the endothelial compartment is not accessible in living humans suffering from COVID-19. Autopsy studies reported presence of viral particles in human endothelial cells³⁴, but infection of endothelial cells by SARS-CoV has been questioned⁵⁵. In SARS-CoV-2 infected non-human primates viral infection of endothelial cells was not observed⁴⁶. Here, we found that endothelial cells showed a rapid and strong induction of anti-viral response genes, but considering the absence of histopathological evidence for intraendothelial virus, we speculate that virus-positive endothelial cells found by scRNA-Seq were not infected, but were rather an artifact originating from contact with ambient virus or its RNA^{2,9}. Concomitant cellular and molecular inflammatory responses in blood suggested that systemic responses were additive to direct, local endothelial cell activation. Notably, this observation is in line with our recent findings that virus-free plasma of COVID-19 patients induced significant endothelial gap formation and loss of junctional VE-cadherin in human endothelial monolayers and lung tissue³³. Endothelialitis, as observed in autopsies of deceased COVID-19 patients, was also found in infected hamsters^{2,9} and corresponded to their transcriptional pro-inflammatory chemokine responses³⁴. Histopathological evidence of pronounced lymphocyte trafficking via capillary endothelial cells also correlated with endothelial *Ccl8* expression.

Lymphocyte recruitment in response to CXCR3 and CCR5 targeting chemokines resulted in the presence of CD4⁺ and CD8⁺ T cells with cytotoxic expression pattern in lungs starting at 3 dpi. Most importantly, viral clearance coincided with appearance of effector T and NK cells stressing their relevance for resolution of SARS-CoV-2 infection and highlighting their importance in vaccination strategies. Studies from other coronaviruses suggest that type 1 immunity is the primary mechanism controlling the infection^{56,57}. In severe COVID-19, blood CD4⁺ T, CD8⁺ T and NK

cells expressed markers of exhaustion⁵⁸, a finding not mirrored in moderately sick Syrian hamsters. In contrast, T and NK responses were effective and self-resolving. This matches observations of broad T cell antigen-specificity in the majority of resolved cases independent of mild or severe infection⁵⁹. In our study, we found SARS-CoV-2 neutralizing antibodies at 5 dpi, likely of IgM type, as early appearance and corresponding elevated IgM protein levels suggested. Seroconversion in COVID-19 patients occurred 7 to 14 days post diagnosis with IgG titers appearing at later time points^{60,61}.

At 14 dpi, infectious virus was no longer detected in hamster lungs, and most transcriptional activity had returned to basal levels. Upregulation of mitotic markers in AT2 cells may reflect regeneration mechanisms after clearing the infection.

The pulmonary capillary microvascular niche in lungs supports alveolar epithelial repair mechanisms following injury, e.g. by secretion of MMP14, VEGF, thrombospondin-1 (THBS1)⁶². Analysis of pulmonary endothelial cell subclusters revealed that bronchial, pulmonary capillary and pulmonary vein endothelial cells showed increased expression of *Thbs1* at 5, but not 14 dpi. Similarly, no increase in *Mmp14* or *Vegf* expression was detected at 14 dpi. In murine influenza characterized by lung injury and pronounced alveolar damage, a pulmonary population of proliferating endothelial cells is present at 14 dpi⁶³ that was absent in SARS-CoV-2 infected Syrian hamsters, indicating that the alveolar endothelial and epithelial damage remained moderate in our model. Most notably, lung endothelial cells showed an anti-fibrotic gene signature at 14 dpi (*Nr4a1*⁶⁴, *Akap12*⁶⁵, *Nrarp* (downstream of Notch-signaling)⁶⁶, indicating regeneration rather than repair of lung tissue, thereby matching histopathology findings.

Taken together, we provide evidence that Syrian hamsters recapitulate the course of moderate human SARS-CoV-2 infection. Hamsters displayed nearly prototypic antiviral immune responses starting with rapid, yet self-restricted neutrophilic response, along with a fast and strong monocytic innate immune response following activation after virus uptake, augmenting local anti-viral responses and pro-inflammatory CC chemokine production recruiting a potent type 1 T cell response that probably contributed to elimination of pulmonary residing virus via cytotoxic effector mechanisms. Neutralizing antibodies of IgM type aided in preventing viral spread and fostered cellular virus uptake. Viral infection and inflammatory response in and by lung epithelium is not predominant. Upon successful elimination of virus,

alveolar epithelial repair mechanisms started, along with endothelial suppression of fibrotic programs, thus enabling pulmonary regeneration in convalesced hamsters. Hence, Syrian hamsters represent a highly suitable model to study pathophysiology of moderate COVID-19, virus-directed and immunomodulatory therapies, and potentially vaccines. SARS-CoV-2 infected Syrian hamsters mount immune responses consistent with COVID-19 patients and enable for detailed investigations on the kinetics and role of specific cell populations, highlighting the dominant contribution of monocytic macrophages, endothelial cells and T cells to inflammatory responses and resolution of SARS-CoV-2 infection.

Limitations of Study

Although we present several lines of evidence suggesting a comparable course of disease in Syrian hamsters and moderate COVID-19 in humans, the extent to which results from this animal model can be translated to human patients is limited. This limitation particularly arises from the unavailability of human samples from time points post infection, yet pre symptom onset, as well as lung tissue samples from living human subjects. Due to the limited amount of molecular tools and reagents available for hamsters, such as antibodies, it is not possible to confirm key findings from our transcriptomic analysis e.g. by immunostaining of tissue sections or by ELISAs for cytokines in the blood.

Data and code availability

Raw and processed data is available at the NCBI gene expression omnibus, entry GSE162208. The code used for data analysis is available at github.com, <https://github.com/Berlin-Hamster-Single-Cell-Consortium>. Further supplementary data is available at <http://www.mdc-berlin.de/singlecell-SARSCoV2>.

Acknowledgments: The authors sincerely thank Drs. Jasmin Lienau and Alexis Vogelzang for excellent manuscript and figure editing. Computation has been performed on the HPC for Research cluster of the Berlin Institute of Health. The authors thank Angela Linke, Michaela Scholz and Simon Dökel for excellent technical assistance with histopathology and ISH.

This research was funded by a Berlin Institute of Health (BIH) grant to G.N., a German Federal Ministry of Education and Research, Germany (BMBF) grant to M.W., grant number CAPSyS (01ZX1604B), and by a German Research Foundation

(DFG) grant to JT and ADG, grant number SFB-TR84 Z01b. G.N., S.-M. W. and M.W. are supported by the German Ministry of Education and Research (BMBF) and by the Agence nationale de la recherche (ANR) in the framework of MAPVAP (16GW0247). A.D.G. is supported by BMBF (NUM-COVID 19, Organo-Strat 01KX2021) and Einstein Foundation 3R (EZ-2020-597 FU). N.S. is supported by DFG, grant number SFB-TR84 B01, C09 und Z02. C.G. is supported by BMBF (NUM-COVID 19, Organo-Strat 01KX2021) and BIH. M.R. is supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001134), the UK Medical Research Council (FC001134), and proteomic work in this manuscript has been conducted as part of the National Research Node 'Mass spectrometry in Systems Medicine (MSCoresys) BMBF, under grant agreement 031L0220. M.W. is supported by the German Research Foundation (SFB-TR84 C06 and C09, SFB1449 B02), by the German Ministry of Education and Research (BMBF) in the framework of CAPSyS-COVID (01ZX1604B), PROVID (01KI20160A), SYMPATH (01ZX1906A), NUM-NAPKON (01KX2021) and by the Berlin Institute of Health (CM-COVID).

Author Contributions: Conceptualization, G.N., E.W., J.T and M.W.; Methodology, G.N., E.W., P.P., D.P., D.V., J.K., F.P., K.D., M.M., V.F., B.O., S.A., T.H., M.R., A.D.G., J.T.; Software/Data analysis, G.N., E.W., P.P., D.P., F.P., K.D., M.M., V.F., B.O., S-M.W., S.A., T.H., M.R., J.T.; Investigation, G.N., E.W., P.P., D.P., D.V., J.K., F.P., K.D., M.M., V.F., B.O., S-M.W., S.A., T.H., C.D., L.E.S., J.T., M.W.; resources, M.M., C.D., N.S., M.R., D.B., A.D.G., C.G., M.L., J.T., M.W.; data curation, E.W.; writing—original draft preparation, G.N., E.W., J.T. and M.W.; writing—review and editing, G.N., E.W., P.P., D.P., J.K., F.P., K.D., M.M., V.F., B.O., S-M.W., C.D., L.E.S., N.S., M.R., D.B., A.D.G., C.G., M.L., J.T., M.W.; Supervision, G.N., E.W., J.T., C.G., M.L. and M.W.; Project administration, G.N.; Funding acquisition, G.N., J.T. and M.W.. All authors have read and agreed to the published version of the manuscript.”

Declaration of Interests: G.N. received funding for research from Biotest AG. E.W., P.P., D.P., D.V., J.K., F.P., K.D., M.M., V.F., B.O., S-M.W., S.A., T.H., B.S., C.D., L.E.S., N.S., M.R., D.B., A.D.G., C.G., M.L., J.T declare no conflict of interest.

M.W. received funding for research from Actelion, Bayer Health Care, Biotest AG, Boehringer Ingelheim, Noxxon, Pantherna, Quark Pharma, Vaxxilon, and for advisory from Actelion, Aptarion, Astra Zeneca, Bayer Health Care, Berlin Chemie, Biotest, Boehringer Ingelheim, Chiesi, Glaxo Smith Kline, Novartis, Noxxon, Pantherna, Teva and Vaxxilon.

The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

Funding: German Federal Ministry of Education and Research (BMBF), German Research Foundation (DFG) and Berlin Institute of Health (BIH).

Figure Legends

Figure 1: Single-cell dynamics in lungs and blood of SARS-CoV-2 infected Syrian hamsters

(a), UMAP plot of identified cell populations in Syrian hamster lungs. (b), Cell count of isolated cells per lung lobe over time (2, 3, 5 and 14 dpi) and control group (naïve, “d0”). (c), Count of hematopoietic cells per lung lobe in naïve hamsters and over time pi. (d), Changes in cellular density of lung cells in UMAP projection. Coloration indicates log2 fold change between control group and 5 dpi. (e), Percentage of hematopoietic cells per lung lobe in naïve hamsters and over time pi. (f), UMAP plot of identified cell populations in blood samples. (g), Cell count of isolated cells per mL blood in naïve hamsters and over time pi. (h), Percentage of identified cell populations in blood samples over time pi and naïve animals. (i), Neutrophil–lymphocyte ratio in blood samples over time pi and naïve animals. (a, d and f), Clusters defined by Louvain clustering, $n = 3$ per time point. (b, c, e, g, h and i), Data display means $\pm$ SD. $n = 3$ per time point. Ordinary one-way ANOVA, Sidak’s multiple comparisons test versus corresponding 0 dpi (naïve). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$

Figure 2: Proteomics analysis recapitulates transcriptomics and human COVID-19 patient data

(a), Temporal evolution of gene ontology/biological process terms connected with immune system response in lung tissue (left part) and in serum fluid (right part), for the indicated time points compared to samples from uninfected animals. Enriched terms were filtered for terms mentioning “immune”, “interferon”, “neutrophil”, “T cell” and “B cell”. Size of dots correspond to the inverse of the false discovery rate. (b), Expression values for differentially regulated proteins in hamster serum (control 3 dpi, $p.val < 0.01$) and lung (control 5 dpi, $p.val < 0.01$) that correlate with disease severity in human plasma. Controls from different days are plotted together. The thick line represents median of all values, lower and upper hinges correspond to medians of lower and upper half of set, respectively. Whiskers extend to a maximum of 1.5 times distance between first and third quartile. All values are shown. (c) Expression values for the differentially expressed proteins *Lgals3* and *Lgals3bp* (only detected in lung samples).

Figure 3: Induction of inflammatory mediators are strongest and earliest in myeloid cells

Dotplots of differentially expressed cytokines and inflammatory mediators in lungs. Shown are genes that display a significant absolute $\log_2$ -transformed fold change of at least one in at least one comparison, and are grouped into four categories indicated on the left. Coloration and point size indicate $\log_2$ -transformed fold changes and P values, respectively, of genes at 2 dpi relative to control groups (naïve). Adjusted P values were calculated by DEseq2 using Benjamini-Hochberg corrections of Wald test p values. Genes are ordered by unsupervised clustering, cell type as in Figure 1.

Figure 4: Transcriptional response to SARS-CoV-2 infection is strong in myeloid and moderate in epithelial cells

(a, b), Dotplot of differentially expressed genes in lungs (a) and blood (b). Shown are genes that are in at least one cell type among the top 4 most changing genes as ranked by adjusted p value. Example: top 4 most changing genes in alveolar macrophages are *Ybx3*, *Rps15*, *Rps10*, and *Uba52*. Coloration and point size indicate $\log_2$ -transformed fold changes and p values, respectively, of genes at 2 dpi

relative to control groups (naïve). Adjusted p values were calculated by DEseq2 using Benjamini-Hochberg corrections of Wald test p values. Cell types and genes are ordered by unsupervised clustering. (c), Top, fraction of monocytic macrophages expressing *Cxcl10* in blood and lungs from naïve animals and 2 dpi. Bottom, boxplots of *Cxcl10* gene expression values of cells positive for *Cxcl10* expression. Significance levels were calculated using generalized linear mixed-effects models for bar plot and a Wilcoxon rank sum test on all cells (i.e. not only the ones expressing the gene) for boxplots. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. See materials and methods for details. (d), As in (c), but only in lungs, all time points and both alveolar epithelial cells type 2 (AT2) and monocytic macrophages. Displayed are values for *Isg15* (left) and *Cxcl10* (right). For all bar plots, data display means $\pm$ SD, $n = 3$ per time point. For all boxplots, lower and upper hinges correspond to first and third quartiles. Whiskers extend to a maximum of 1.5 times the distance between first and third quartile. Outliers beyond are marked by single dots.

Figure 5: Virus RNA in monocytic macrophages leads to dose-dependent activation of pro-inflammatory cytokines by TLR signaling

(a), Feature plots of entry factor expression in UMAP projection. Coloration indicates expression values of indicated genes. (b-e), Detection of viral RNA by in situ-hybridization. Labeled are supposed endothelium (b, hash), bronchial epithelial cells (b, arrowhead), AT1 (c, arrowhead) and AT2 (c, arrow). (d, inset), macrophages containing viral RNA and cell debris (arrowhead), and an example of high levels of viral RNA without cell debris in the inset (arrow). For (b-e), red signals viral RNA and blue hemalaun counterstain. Time points: (b-c) from 2 dpi, (d) from 3 dpi, (e) staining control. Bars: (b, d, e) = 50 μ m, (c) = 100 μ m, Inset in (c) = 20 μ m. (f), Cells in the UMAP projection are colored by amount of viral RNA (log10 transformed percentage of viral RNA per cell), along with overview of identified cell types in lungs. (g), Dotplot of cytokine expression in monocytic macrophages containing viral RNA compared to those without viral RNA. Coloration and point size indicate log2 fold change and P value for each time point 2, 3 and 5 dpi. (h, i), Box- and barplots of *Isg15* (h) and *Cxcl10* (i) gene expression in AT2 and monocytic macrophages along, comparing cells containing viral RNA to those without for 2, 3, and 5 dpi. Barplot shows percentage of cells positive for respective gene, with mean $\pm$ SD, $n = 3$. Boxplots show gene expression levels in cells positive for respective gene. (j), Box- and

barplots of *Cxcl10* in monocytic macrophages and fraction of *Cxcl10* positive cells for each time point pi and naïve animals, with cells grouped by increasing virus levels for 2, 3, and 5 dpi. (e and f), for barplots, data display means $\pm$ SD. Significance levels calculated using generalized linear mixed-effects models for barplot and a wilcoxon rank sum test on all cells (i.e. not only the ones expressing the gene) for boxplots. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. See materials and methods for details.

Figure 6: Endothelial cells show subtype and time specific activation of cytokines

(a), UMAP plot of lung endothelial cell subpopulations. (b), Dotplot of differentially expressed genes in lung endothelial cell subpopulations over time. Shown are genes that are in at least one cell type among the top 10 most changing genes as ranked by adjusted p value. (c), Dotplot of differentially expressed genes from two curated sets as indicated in lung endothelial cell subpopulations over time pi. For both (b) and (c), coloration and point size indicate log₂-transformed fold changes and P values, respectively, of genes at 2 dpi relative to control groups (naïve). Adjusted P values were calculated by DEseq2 using Benjamini-Hochberg corrections of Wald test P values.

Figure 7: Syrian hamsters exhibit a strong cytotoxic T/NK cell response at day 5 post infection

(a), UMAP plot of lung T/NK cell subclustering indicating cell subpopulations. (b), Count of lung T cell subpopulations and NK cells per lung lobe. (c), Dotplot of master regulators of T cell differentiation and effector genes. Coloration and point size indicate log₂ fold change and P value, respectively. (d), Fraction of *Ifng*⁺ cells in CD4⁺ T, CD8⁺ T and NK cells at 2, 3, 5 and 14 dpi and naïve. (e), Fraction of *Gzma*⁺ cells in CD8⁺ T cells at 2, 3, 5 and 14 dpi and naïve. (f), Fraction of AT2 cells, monocytic macrophages, endothelial cells and AT1 cells containing both at least one cell type marker gene (AT2: *Sftpa1*, *Sftpc* – monocytic macrophages: *Fcn1*, *Saa3* – endothelial cells: *Cldn5*, *Plvap* – AT1: *Ager*, *Aqp5*) together with *Gzma*. Data display means $\pm$ SD, $n = 3$ per time point. (g), Histopathology of blood vessels at different time points, bar: 50 μ m. (h) Serum neutralization titers of SARS-CoV-2 infected

hamsters at 5 and 14 dpi. Serum titers of naïve, 2 and 3 dpi did not neutralize up to detection limit 1:4 (dotted line). Data display n = 3 with mean per time point.

Methods

Ethics statement and animal husbandry

All experiments involving animals were approved by institutional and governmental authorities (Freie Universität and LaGeSo Berlin, Germany). Female and male Syrian hamsters (*Mesocricetus auratus*; breed RjHan:AURA, Janvier Labs, France) were housed in biosafety level 3 (BSL-3) conditions in individually ventilated cages with enrichment. Food and water was provided *ad libidum*. Daily cage temperature and relative humidity measurements ranged from 22–24 °C and 40–55 %, respectively. Animals were acclimatized for a minimum of 7 days prior to infection.

Virus Stocks

SARS-CoV-2 isolate (BetaCoV/Germany/BavPat1/2020)⁶⁷ was kindly provided by Niemeyer and Drosten, Charité Berlin, Germany. Virus stocks were propagated under BSL-3 conditions in Vero E6 cells (ATCC CRL-1586). All hamsters described here received virus from the same batch.

Animal infection

At 10–12 weeks of age hamsters were intranasally infected with 1×10^5 pfu SARS-CoV-2 as previously described². Clinical signs and weight were monitored daily. Animals with >15 % body weight loss over 48 h were euthanized in accordance with animal-use protocols. Naïve (n = 3) and infected hamsters were randomly selected for analyses at time points 2, 3, 5 or 14 days post infection (dpi) (n = 3, each). Euthanasia and exsanguination were performed as previously described². 1 mL peripheral blood was collected in EDTA-coated syringes. The left lung lobe was collected for histopathology, the right caudal lobe for single-cell analysis, the right cranial lobe for virological assessments and the right medial for bulk RNA as well as proteomics analysis. Experimental design and analysis are summarized in the supplemental material (Figure S1).

Viral burden assessment

Virus titers were determined by serial dilutions of lung homogenates (50 mg) plated on Vero E6 cells, cells were fixed in 10 % formalin, stained with crystal violet (0.75% aqueous solution) and plaques were counted as previously described ².

For RNA extractions and quantitative RT-PCR, RNA from oropharyngeal swabs, lung tissue and whole blood was isolated with the innuPREP Virus DNA/RNA Kit (Analytic Jena). One-step RT qPCR reaction with the NEB Luna Universal Probe One-Step RT-qPCR (New England Biolabs) and the 2019-nCoV RT-qPCR primers and probe E_Sarbeco ⁶⁸ quantified viral RNA. Normalization of viral RNA to cellular *Rp18* and standard curves for quantification were generated as previously described ². Viral RNA copies were calculated per 1×10^5 hamster *Rp18* transcripts. Primers and probes are listed in the Supplemental Material (Table S1).

Measurement of neutralizing antibodies titer

Serum neutralization tests were performed by two fold serial dilutions (1:4 to 1:512) of complement inactivated (56°C, 2 h) hamster serum plated on sub-confluent monolayers of Vero E6 cells. 50 pfu SARS-CoV-2 were added per well and incubated for 72 h at 37°C, fixed with 10 % formalin for 24 h and stained with crystal violet (0.75% aqueous solution). Serum neutralization was considered effective in wells that did not show any cytopathic effect, the highest effective dilution was counted.

Histopathology and in situ-hybridization of SARS-CoV-2 RNA

For histopathology and *in situ*-hybridization (ISH), lungs were processed as described ². Left lung lobes were immersion-fixed in 10 % formalin, pH 7.0, for 48 h, embedded in paraffin, and cut into 2 µm sections. Hematoxylin and eosin (HE) staining and *in situ*-hybridizations were performed as described ⁷ using the ViewRNA™ ISH Tissue Assay Kit (Invitrogen) following the manufacturer's instructions with minor adjustments. SARS-CoV-2 RNA was localized with probes detecting N gene sequences (NCBI database NC_045512.2, nucleotides 28,274 to 9533, assay ID: VPNKRHM). An irrelevant probe for detection of pneumolysin was used to control for sequence-specific binding ⁴. Amplifier and label probe hybridizations were performed following the manufacturer's instructions using fast red as chromogen with hemalaun counterstain. Tissues were histopathologically evaluated by board-certified veterinary pathologists (KD, ADG) in a blinded fashion

following standardized recommendations ⁹, including pneumonia-specific scoring parameters ⁴¹ as previously described for SARS-CoV-2 infection in hamsters ².

Single Cell Isolation from Whole Blood and hamster lungs

Protocols were adapted for BSL-3 facility regulations. For isolation of cells from whole blood, 250 μ L blood were lysed in red blood cell lysis buffer (BioLegend), washed and centrifuged according to the manufacturer's instructions. Resulting RBC-free pellets were resuspended in low-BSA buffer (1 $\times$ PBS, 0.04 % BSA), filtered with 40 μ m FloMi filters (Merck) and counted by hemocytometer in trypan blue.

For isolation of single cells caudal lung lobe was removed and placed in storage medium (1 $\times$ PBS, 0.5 % BSA) until further processing. Storage and isolation media contained 2 μ g/mL ActinomycinD. Tissues and cells were centrifuged at 350 $\times$ *g* for 6 minutes at 4 $^{\circ}$ C. Lung lobes were mechanically disassociated with tweezers for 2 minutes in enzymatic digestion medium containing 3.4 mg/mL Collagenase CIs II (Merck) and 1 mg/mL DNase I (PanReac AppliChem) in 2 mL Dispase medium (Corning) per lung lobe followed by 30 minutes incubation at 37 $^{\circ}$ C and 5 % CO₂. After dissociation of digested lung tissue, cell suspensions were pressed through 70 μ m cell strainers with plungers. Red blood cells were lysed (BioLegend), washed with an excess of PBS/BSA and resuspended in low-BSA buffer (1 $\times$ PBS, 0.04 % BSA), and filtered with 40 μ m low-volume FloMi filters (Merck). Cells were counted in trypan blue.

Single Cell RNA Sequencing

Barcoding, cDNA Library generation and sequencing; Filtered cells were adjusted to a final concentration of ~1,000 cells / μ L in 1 $\times$ PBS with 0.04% BSA and subjected to partitioning into Gel-Beads-in-Emulsions (GEMs) aiming to recover 6,000 single cells per hamster and organ by following the instructions for the Chromium Next GEM Single Cell 3' GEM, Library & Gel Bead Kit v3.1 (10x Genomics). Resulting single-cell libraries were quantified using Qubit (ThermoFisher) and quality-controlled using the Bioanalyzer system (Agilent). Sequencing was performed on a Novaseq 6000 device (Illumina), with SP or S1 flow cells (read1: 28 nucleotides, read2: 64 nucleotides).

Bulk RNA sequencing

For lung RNA Bulk Sequencing the medial lung lobe was removed and stored in RNA Later Solution for a maximum of 24 hours at 4 °C (ThermoFisher). Lung tissue was homogenized using the TissueLyser II system (Qiagen) and homogenates stored in Trizol reagent (Zymo research). For WBC RNA Bulk Sequencing, white blood cells were isolated as described for scSeq followed by lysis in Trizol reagent. RNA extractions were performed according to the Direct-zol RNA Miniprep protocol (Zymoresearch). Bulk RNA sequencing libraries constructed using the Nebnext Ultra II Directional RNA Library Prep Kit (New England Biolabs), and sequenced on a Nextseq 500 device with read length 76.

Proteomics

Proteomics sample preprocessing

Lung tissue and serum were added to lysis and inactivation buffer (RIPA) and boiled for 10 min at 95 °C before storage at -80 °C. Samples were thawed on ice, volume was adjusted to 50 µl with water and 25 µl of 50 U benzonase, 50 mM ABC, 2 mM MgCl₂ added before incubation for 30 min at 37 °C. Lysates were processed on a Biomek i7 workstation using the SP3 protocol as previously described with single-step reduction and alkylation⁶⁹. Samples were used for LC-MS/MS analysis without additional conditioning or clean-up. For proteomics, conventional approaches were combined with generation acquisition methods, (i.e. Scanning SWATH)⁷⁰ coupled with high flow chromatographic separation.

Liquid Chromatography–Mass Spectrometry Analysis (LC–MS)

High-throughput analysis of serum and lung tissue; Peptide separation has been accomplished in a 5-minute water to acetonitrile gradient on an Agilent Infinity II HPLC coupled to a Sciex Triple TOF 6600 mass spectrometer (IonDrive TurboV Source) operating in ScanningSWATH mode with minor changes in the liquid chromatography method⁷⁰. As follows: 5 µg of peptides were loaded and resolved in a linear gradient from 1-35 % buffer B in 4.5 min before increasing to 40 % B in 0.5 min and washing for 0.2 min with 80 % buffer B before equilibration for 2.2 min with initial conditions (buffer A: 0.1 % formic acid, buffer B: 100 % ACN, 0.1 % formic acid).

Computational proteomics; For *Mesocricetus auratus* serum samples, a project specific library was generated by gas-phase fractionation (GPF), whereas the lung tissue library was constructed using standard settings in library free mode with DIA-NN (version 1.7.12)⁷¹. Proteins were annotated using the *M. auratus* genome sequence generated in this work. The libraries were automatically refined based on the project dataset at 0.01 global q-value (using the “Generate spectral library” option in DIA-NN) as previously described¹⁹. The output was filtered at 0.01 false discovery rate (FDR) at the peptide level. For GPF, 6 single 1 µg injections of pooled serum samples were analyzed by online nanoflow liquid chromatography tandem mass spectrometry on a Ultimate3000 Thermo Scientific Q Exactive Orbitrap, LC-MS instrument (Thermo Fisher Scientific, Waltham, USA). The peptides were concentrated for 3 min on a trap column (PepMap C18, 5 mm x 300 µm x 5 µm, 100Å, Thermo Fisher Scientific) with a buffer containing 2:98 (v/v) acetonitrile/water containing 0.1% (v/v) trifluoroacetic acid at a flow rate of 20 µl/min. They were separated by a 250 mm LC column (Acclaim PepMap C18, 2 µm; 100 Å; 75µm, Thermo Fisher Scientific). The mobile phase (A) was 0.1 % (v/v) formic acid in water, and (B) 80 % acetonitrile in 0.1 % (v/v) formic acid. In 155 min total acquisition time gradient B increased in 90 min to 25 %, and in 30 min to 40 % with a flow rate of 300 nl/ min. The MS instrument was operated in the data independent mode as followed: the Orbitrap worked in centroid mode with 4 m/z DIA spectra (4 m/z precursor isolation windows at 17,500 resolution, AGC target 1e6, maximum inject time 60 ms, 27 NCE). An overlapping window pattern from narrow mass ranges using window placements (i.e., 395-505, 495-605, 595-705, 695-805, 795-805, 895-905 m/z) was set. Two precursor spectra, a wide spectrum (395-505 m/z at 35,000 resolution) and a narrow spectrum matching the range using an AGC target of 1e6 and a maximum inject time of 60 ms were interspersed every 25 MS/MS spectra at resolution of 17,500. Typical mass spectrometric conditions were as follows: spray voltage, 2.1 kV; no sheath and auxiliary gas flow; heated capillary temperature: 275 °C; normalized HCD collision energy 27 %. As lock mass acted the background ion m/z 445.1200.

Materials Proteomics; Hydrophobic Sera-Mag magnetic carboxylate modified particles (44152105050250 Fisher Scientific), hydrophilic Sera-Mag magnetic carboxylate modified particles (24152105050250 Fisher Scientific), Twintec skirted low bind plates (0030129512 Eppendorf), TCEP (646547 Sigma Aldrich), SDS

904 (A7249.1000 Applichem), CAA (22788 Merck/Millipore), ammonium bicarbonat
 905 (/871.2 Roth), 100 % ACN (955-212 Fisher Scientific), 80 % ethanol (1.00983.2500
 906 Millipore), 230 µl Biomek Tips (B85903 Beckmann Coulter), Eppendorf 500 µl deep
 907 well plates (30501101 Eppendorf), Waters Acquity UPLC 700 µl plates (186005837
 908 Waters GmbH) Sequencing grade modified Trypsin (V5117 Promega), Pierce
 909 Quantitative Fluorometric Peptide Assay (number 23290), formic acid (85178 Thermo
 910 Scientific), water (1.15333.2500 Merck), protease inhibitor cocktail complete mini
 911 (Roche 04693124001), benzonase nuclease (Sigma Aldrich E1014-25KU)

912 *Data pre-processing*; Four serum samples showed low quality and were removed.
 913 Peptides with excessive missing values (> 30% per group) were excluded from
 914 analysis. Batch correction was applied. The peptide matrix was filtered using factor
 915 “Proteotypic” keeping only peptides belonging to one protein group. To obtain a
 916 quantitative protein data matrix, the log2-intensities of peptides belonging to one
 917 protein group were summarised by “maxLFQ” method ⁷² into protein log intensity.

918 *Statistical analysis*; Statistical analysis of proteomics data was carried out using
 919 internally developed R scripts. Linear modelling was based on the R package
 920 LIMMA ⁷³. Following model was applied to the sets of lung/serum samples (log(p) is
 921 log2 transformed expression of a protein): $\log(p) \sim 0 + \text{Class}(\text{Day}) + \text{Gender}$
 922 Here, categorical factor Class(Day) has 8 levels:
 923 Infected(D02), Infected(D03), Infected(D05), Infected(D14),
 924 Control(D02), Control(D03), Control(D05), Control(D14)
 925 Categorical factor Gender has two levels: male, female.

926 The following contrasts were evaluated to trace time dependence of response to viral
 927 infection (Note that Contrast5 addresses the average difference between infected
 928 and recovered animals and Contrast6 addresses the difference between infected and
 929 control animals on average):

930 Contrast1: Infected(D02) – Control(D02)
 931 Contrast2: Infected(D03) – Control(D03)
 932 Contrast3: Infected(D05) – Control(D05)
 933 Contrast4: Infected(D14) – Control(D14)

934 Contrast5: $[\text{Infected}(\text{D02}) + \text{Infected}(\text{D03}) + \text{Infected}(\text{D05})] / 3 - [\text{Control}(\text{D02}) +$
 935 $\text{Control}(\text{D03}) + \text{Control}(\text{D05})] / 3 - [\text{Infected}(\text{D14}) - \text{Control}(\text{D14})]$
 936 Contrast6: $[\text{Infected}(\text{D02}) + \text{Infected}(\text{D03}) + \text{Infected}(\text{D05})] / 3 - [\text{Control}(\text{D02}) +$
 937 $\text{Control}(\text{D03}) + \text{Control}(\text{D05})] / 3$

In serum set of samples there was only one control group at 3 dpi and it was used to build contrasts replacing control groups at other dpi's.

For finding regulated features following criteria were applied:

Significance level alpha was set to guarantee false discovery rate below 10% at the response maximum (5 dpi) in both sample types. We found that alpha = 0.01 was delivering regulated proteins with Benjamini–Hochberg FDR below 8% in lung tissue and below 6% in serum and used it for feature selection.

The log fold change criterion was applied to guarantee that the measured signal is above the average noise level. As such we have taken mean residual standard deviation of linear model: $\log_2(T) = \text{mean residual SD of linear modelling}$ ($T = 1.45$ in lung and $T=1.37$ in serum).

Functional analysis of proteomics data; Functional analysis was carried out using gprofiler2 R package⁷⁴. For selecting the most (de)regulated GO terms we applied filter: $2 \leq \text{term size} \leq 200$. Analyses for each Contrast 1 – 6 (Table 1) and then all in parallel were carried out with Benjamini–Hochberg FDR threshold 0.2. Organism for search was specified as mauratus – Mesocricetus auratus (Syrian hamster). Statistical domain scope was set to custom, list of all identified proteins was provided as background.

Statistical Analyses of clinical hamster data

Graph-Pad Prism v8 software was used for statistical analysis of clinical data. The statistical details of all analyzed experiments are given in the respective figure legends.

Annotation of the *M. auratus* genome

The *M. auratus* genome (MesAur1.0) sequence and annotation (gtf file, version 99) was downloaded from Ensembl. We noticed that 3'-UTRs in this annotation were frequently too short to capture all transcriptome reads and particularly the 3' end reads in single-cell RNA-sequencing, so we extended all 3'-UTRs for coding genes by 1,000 bp. The *Ifit2* gene was extended by 2,000 bp. For key genes analyzed in this manuscript, we verified that this extension did not lead to overlaps with downstream genes.

The Ensemble annotation was extended by mapping ENSEMBL gene ids without annotated gene names to entrez identifiers and to the homolog associated gene

names using biomaRt ⁷⁵. Wherever existing, we extracted the gene name from the NCBI's All_Mammalia.gene_info (download from ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/GENE_INFO/Mammalia/) table, capturing 1067 gene names. Otherwise we used available homolog associated gene names yielding 1193 additional entries.

Analysis of bulk RNA-sequencing data

Reads were aligned to the genome using hisat2 ⁷⁶ and quantified using quasR ⁷⁷. We then performed gene set enrichment analysis with tmod ⁷⁸ and Hallmark, Reactome and GO BP gene sets from MSigDB v7.0 ⁷⁹, ranking genes by the product of the sign of the log2 fold change and log10 adjusted p-value and converting hamster gene names to human using the biomaRt mouse-to-human mapping.

Analysis of single-cell RNA-sequencing data

Data analysis was done in R ⁸⁰, using Seurat ⁸¹ and packages from tidyverse ⁸² and glmer ⁸³. All used code with annotation is available through Github at <https://github.com/Berlin-Hamster-Single-Cell-Consortium>.

Raw single-cell sequencing data was processed using CellRanger 3.1.0 (10x Genomics) with standard parameters, based on a combined MesAur1.0/SARS-CoV-2 (GenBank entry MN908947) reference. Raw feature barcode matrices from the CellRanger output were read into Seurat using the Read10X function and a Seurat object created using the CreateSeuratObject function. Cells with more than 7 % mitochondrial reads, based on the percentage feature expression of the mitochondrial genes *Cox1*, *Cytb*, *Nd1*, *Nd2*, *Nd4*, *Nd5*, *Nd6* were excluded (reads from other mitochondrial genes were not detected in the data). Furthermore, cells with less than 1000 (lung) or 500 (blood) detected genes were also excluded from downstream analysis. Sample sets (all lung, or all blood, or blood/lung combined from the individual time points) were then integrated using the SCTransform workflow, as illustrated on the Seurat website ⁸⁴. Briefly, the Seurat object was split by the hamster that the data points originated from and separately transformed using SCTransform to normalise and scale the data. To prevent batch specific/animal specific effects from obscuring results, these split objects were integrated using the SelectIntegrationFeatures, PrepSCTIntegration, FindIntegrationAnchors and IntegrateData functions in succession. PCA and UMAP dimensional reduction

analyses respectively were performed on the integrated object, using 30 dimensions for the UMAP as the SCT workflow reportedly shows more robust results with higher dimensionality. Cells were subjected to Louvain clustering using the FindNeighbours and FindClusters (with a resolution parameter of 0.8 for lung samples and 0.5 for the blood samples) functions.

To annotate cell types in the lung scRNAseq data, we used Seurat's TransferData workflow⁸⁴ and two different reference data sets: Tabula Muris⁸⁵ and the Human Lung Cell Atlas⁸⁶. Integration with mouse data was performed using matching gene names between mouse and hamster, while gene names in the human data were converted to mouse using biomaRt. We then used the predicted cell type of the majority of cells in each cluster to guide cluster annotation, also taking into account cell marker genes published in literature and cell marker databases^{87,88}. The following populations were confirmed: Alveolar macrophages (*Siglec⁺*, *Marco⁺*)⁸⁹, interstitial macrophages (*C1qb⁺*)⁹⁰, monocytic macrophages (*Ccr2⁺*, *Ccr5⁺*, *Arg1⁺*)^{91,92}, *Trem14⁺*-monocytes (*Trem14⁺*)⁹³, neutrophils (*S100a8⁺*, *Cxcr2⁺*, *Camp⁺*)^{44,94}, myeloid dendritic cells (mDC) (*Flt3⁺*, *H2-Ab1^{hi}*, *Irf8^{lo}*, *Tcf4^{lo}*) and plasmacytoid dendritic cells (pDC) (*Flt3⁺*, *H2-Ab1^{hi}*, *Irf8^{hi}*, *Tcf4^{hi}*)^{85,95-97}, T / NK / cells (*Cd3e⁺*, *Cd4⁺* or *Cd8a⁺*, *Gzma⁺*, *Nkg7⁺*)^{85,94,98-100}, B cells (*Cd79b⁺*, *Ms4a1⁺*)^{44,101}, alveolar epithelial cells type 1 (*Rtkn2⁺*)⁹⁰, endothelial cells (*Pecam1⁺*)⁸⁹, ciliated epithelial cells (*Foxj1⁺*) [30318149], alveolar epithelial cells type 2 (*Lamp3⁺*)¹⁰¹, smooth muscle cells (*Tagln⁺*, *Acta2⁺*)^{90,102}, fibroblasts (*Dcn⁺*)⁹⁰ as well as myofibroblasts (*Dcn⁺*, *Tagln^{hi}*, *Acta2^{hi}*).

Analysis of single-cell sequencing data for blood samples was similar to that of lung samples with minor exceptions. Following initial clustering, cluster marker genes were identified using the FindAllMarkers function and clusters expressing high levels of erythrocyte marker genes *Snca*, *Fam46c* and *Alas2* were identified as containing erythrocyte contamination¹⁰³⁻¹⁰⁵. Cells in these clusters, as well as a cluster of most likely dead cells, marked by the expression of mitochondrial genes, were removed and the data was re-integrated using the workflow described above. Cell type annotations were assigned to the identified cluster using the follow marker genes: Classical (inflammatory) monocytes (*Ccr2⁺*, *Cx3cr1^{lo}*, *Adgre1⁺*); non-classical (residential) monocytes (*Ccr2⁻*, *Cx3cr1^{hi}*, *Adgre1⁺*)¹⁰⁶⁻¹⁰⁸; mature neutrophils (*Cxcr2⁺*, *S100a8⁺*, *Camp^{lo}*, *Retn^{lo}*, *Ltf^{lo}*) and immature neutrophils (*Cxcr2⁺*, *S100a8⁺*, *Camp^{hi}*, *Retn^{hi}*, *Ltf^{hi}*)^{44,94,109,110}; myeloid dendritic cells (*Flt3⁺*, *H2-Ab1^{hi}*, *Irf8^{lo}*, *Tcf4^{lo}*) and plasmacytoid dendritic cells (*Flt3⁺*, *H2-Ab1^{hi}*, *Irf8^{hi}*, *Tcf4^{hi}*)^{85,95-97}; T cells (*Cd3e⁺*, *Cd4⁺*

or *Cd8a*⁺) and activated T cells (*Cd3e*⁺, *Cd4*⁺ and/or *Cd8a*⁺, *Gzma*⁺)^{85,94,98,100}, natural killer (NK) cells (*Cd3e*⁺, *Nkg7*⁺)^{94,99}; B cells (*Cd79a*⁺, *Ms4a1*⁺)^{44,101,111} and platelets (*Gng11*⁺, *Ppbp*⁺)^{22,112}. While cluster 17 showed no expression of *Ccr2*, the levels of *Adgre1* and *Cd14* were considerable and it was considered as comprising classical monocytes for the purposes of this study¹¹³.

Previously published scRNAseq data of bronchoalveolar lavages originating from COVID-19 patients data from Liao et al.²⁵ was processed using the same (Seurat) workflow in R. We kept cells with less than 10 % mitochondrial reads, less than 50000 UMIs and less than 6000 genes and used IntegrateData to combine different samples. We then again used the Human Lung Cell Atlas reference and TransferData to annotate clusters.

Differential cell density was calculated as previously described¹¹⁴ by plotting the log2 ratio of two separate 2D kernel density estimators interpolated on the UMAP coordinates of each cell.

References

- 1 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* **382**, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).
- 2 Osterrieder, N. *et al.* Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters. *Viruses* **12**, doi:10.3390/v12070779 (2020).
- 3 Imai, M. *et al.* Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. *Proc Natl Acad Sci U S A* **117**, 16587-16595, doi:10.1073/pnas.2009799117 (2020).
- 4 Bertzbach, L. D. *et al.* SARS-CoV-2 infection of Chinese hamsters (*Cricetulus griseus*) reproduces COVID-19 pneumonia in a well-established small animal model. *Transbound Emerg Dis*, doi:10.1111/tbed.13837 (2020).
- 5 Trimpert, J. *et al.* The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection. *Cell Rep* **33**, 108488, doi:S2211-1247(20)31477-7 [pii] 10.1016/j.celrep.2020.108488 (2020).
- 6 Sia, S. F. *et al.* Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. *Nature* **583**, 834-838, doi:10.1038/s41586-020-2342-5 (2020).

1072 7 Kreye, J. *et al.* A Therapeutic Non-self-reactive SARS-CoV-2 Antibody
1073 Protects from Lung Pathology in a COVID-19 Hamster Model. *Cell* **183**, 1058-
1074 1069 e1019, doi:S0092-8674(20)31246-0 [pii]
1075 10.1016/j.cell.2020.09.049 (2020).

1076 8 Lee, A. C. *et al.* Oral SARS-CoV-2 Inoculation Establishes Subclinical
1077 Respiratory Infection with Virus Shedding in Golden Syrian Hamsters. *Cell*
1078 *Rep Med* **1**, 100121, doi:10.1016/j.xcrm.2020.100121
1079 S2666-3791(20)30163-4 [pii] (2020).

1080 9 Gruber, A. D. *et al.* Standardization of Reporting Criteria for Lung Pathology in
1081 SARS-CoV-2-infected Hamsters: What Matters? *Am J Respir Cell Mol Biol* **63**,
1082 856-859, doi:10.1165/rcmb.2020-0280LE (2020).

1083 10 Roberts, A. *et al.* Severe acute respiratory syndrome coronavirus infection of
1084 golden Syrian hamsters. *J Virol* **79**, 503-511, doi:79/1/503 [pii]
1085 10.1128/JVI.79.1.503-511.2005 (2005).

1086 11 Gong, S. R. & Bao, L. L. The battle against SARS and MERS coronaviruses:
1087 Reservoirs and Animal Models. *Animal Model Exp Med* **1**, 125-133,
1088 doi:10.1002/ame2.12017
1089 AME212017 [pii] (2018).

1090 12 Gretebeck, L. M. & Subbarao, K. Animal models for SARS and MERS
1091 coronaviruses. *Curr Opin Virol* **13**, 123-129, doi:10.1016/j.coviro.2015.06.009
1092 S1879-6257(15)00098-X [pii] (2015).

1093 13 Subbarao, K. & Roberts, A. Is there an ideal animal model for SARS? *Trends*
1094 *Microbiol* **14**, 299-303, doi:S0966-842X(06)00127-2 [pii]
1095 10.1016/j.tim.2006.05.007 (2006).

1096 14 Tostanoski, L. H. *et al.* Ad26 vaccine protects against SARS-CoV-2 severe
1097 clinical disease in hamsters. *Nat Med* **26**, 1694-1700, doi:10.1038/s41591-
1098 020-1070-6
1099 10.1038/s41591-020-1070-6 [pii] (2020).

1100 15 Jiang, R. D. *et al.* Pathogenesis of SARS-CoV-2 in Transgenic Mice
1101 Expressing Human Angiotensin-Converting Enzyme 2. *Cell* **182**, 50-58 e58,
1102 doi:S0092-8674(20)30622-X [pii]
1103 10.1016/j.cell.2020.05.027 (2020).

1104 16 Winkler, E. S. *et al.* SARS-CoV-2 infection of human ACE2-transgenic mice
1105 causes severe lung inflammation and impaired function. *Nat Immunol* **21**,
1106 1327-1335, doi:10.1038/s41590-020-0778-2
1107 10.1038/s41590-020-0778-2 [pii] (2020).

1108 17 Lagunas-Rangel, F. A. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-
1109 reactive protein ratio in patients with severe coronavirus disease 2019
1110 (COVID-19): A meta-analysis. *J Med Virol* **92**, 1733-1734,
1111 doi:10.1002/jmv.25819 (2020).

1112 18 Liu, J. *et al.* Longitudinal characteristics of lymphocyte responses and cytokine
1113 profiles in the peripheral blood of SARS-CoV-2 infected patients.
1114 *EBioMedicine* **55**, 102763, doi:S2352-3964(20)30138-9 [pii]
1115 10.1016/j.ebiom.2020.102763 (2020).

1116 19 Messner, C. B. *et al.* Ultra-High-Throughput Clinical Proteomics Reveals
1117 Classifiers of COVID-19 Infection. *Cell Syst* **11**, 11-24 e14,
1118 doi:10.1016/j.cels.2020.05.012 (2020).

1119 20 Demichev, V. *et al.* A time-resolved proteomic and diagnostic map
1120 characterizes COVID-19 disease progression and predicts outcome. *medRxiv*,
1121 2020.2011.2009.20228015, doi:10.1101/2020.11.09.20228015 (2020).

1122 21 Zeng, H. L. *et al.* Proteomic characteristics of bronchoalveolar lavage fluid in
1123 critical COVID-19 patients. *FEBS J*, doi:10.1111/febs.15609 (2020).

1124 22 Schoggins, J. W. Interferon-Stimulated Genes: What Do They All Do? *Annu*
1125 *Rev Virol* **6**, 567-584, doi:10.1146/annurev-virology-092818-015756 (2019).

1126 23 Hou, Y. J. *et al.* SARS-CoV-2 Reverse Genetics Reveals a Variable Infection
1127 Gradient in the Respiratory Tract. *Cell* **182**, 429-446 e414,
1128 doi:10.1016/j.cell.2020.05.042 (2020).

1129 24 Olajuyin, A. M., Zhang, X. & Ji, H. L. Alveolar type 2 progenitor cells for lung
1130 injury repair. *Cell Death Discov* **5**, 63, doi:10.1038/s41420-019-0147-9
1131 147 [pii] (2019).

1132 25 Liao, M. *et al.* Single-cell landscape of bronchoalveolar immune cells in
1133 patients with COVID-19. *Nat Med* **26**, 842-844, doi:10.1038/s41591-020-0901-
1134 9
1135 10.1038/s41591-020-0901-9 [pii] (2020).

1136 26 Morse, C. *et al.* Proliferating SPP1/MERTK-expressing macrophages in
1137 idiopathic pulmonary fibrosis. *Eur Respir J* **54**, doi:10.1183/13993003.02441-
1138 2018 (2019).

1139 27 Chua, R. L. *et al.* COVID-19 severity correlates with airway epithelium-immune
1140 cell interactions identified by single-cell analysis. *Nat Biotechnol* **38**, 970-979,
1141 doi:10.1038/s41587-020-0602-4
1142 10.1038/s41587-020-0602-4 [pii] (2020).

1143 28 Cantuti-Castelvetri, L. *et al.* Neuropilin-1 facilitates SARS-CoV-2 cell entry and
1144 infectivity. *Science* **370**, 856-860, doi:10.1126/science.abd2985 (2020).

1145 29 Daly, J. L. *et al.* Neuropilin-1 is a host factor for SARS-CoV-2 infection.
1146 *Science* **370**, 861-865, doi:10.1126/science.abd3072 (2020).

1147 30 Davies, J. *et al.* Neuropilin1 as a new potential SARSCoV2 infection mediator
1148 implicated in the neurologic features and central nervous system involvement
1149 of COVID19. *Mol Med Rep* **22**, 4221-4226, doi:10.3892/mmr.2020.11510
1150 (2020).

1151 31 Liu, T., Zhang, L., Joo, D. & Sun, S. C. NF-kappaB signaling in inflammation.
1152 *Signal Transduct Target Ther* **2**, doi:10.1038/sigtrans.2017.23 (2017).

1153 32 Schneider, W. M., Chevillotte, M. D. & Rice, C. M. Interferon-stimulated genes:
1154 a complex web of host defenses. *Annu Rev Immunol* **32**, 513-545,
1155 doi:10.1146/annurev-immunol-032713-120231 (2014).

1156 33 Michalick, L. *et al.* Plasma mediators in patients with severe COVID-19 cause
1157 lung endothelial barrier failure. *Eur Respir J*, doi:2002384 [pii]
1158 10.1183/13993003.02384-2020
1159 13993003.02384-2020 [pii] (2020).

1160 34 Ackermann, M. *et al.* Pulmonary Vascular Endothelialitis, Thrombosis, and
1161 Angiogenesis in Covid-19. *N Engl J Med* **383**, 120-128,
1162 doi:10.1056/NEJMoa2015432 (2020).

1163 35 Ford, J. *et al.* CCL7 Is a Negative Regulator of Cutaneous Inflammation
1164 Following Leishmania major Infection. *Front Immunol* **9**, 3063,
1165 doi:10.3389/fimmu.2018.03063 (2018).

1166 36 Blaszczyk, J. *et al.* Complete crystal structure of monocyte chemotactic
1167 protein-2, a CC chemokine that interacts with multiple receptors. *Biochemistry*
1168 **39**, 14075-14081, doi:10.1021/bi0009340 (2000).

1169 37 Schnoor, M., Alcaide, P., Voisin, M. B. & van Buul, J. D. Crossing the Vascular
1170 Wall: Common and Unique Mechanisms Exploited by Different Leukocyte
1171 Subsets during Extravasation. *Mediators Inflamm* **2015**, 946509,
1172 doi:10.1155/2015/946509 (2015).

1173 38 Johansen, M. D. *et al.* Animal and translational models of SARS-CoV-2
1174 infection and COVID-19. *Mucosal Immunol* **13**, 877-891, doi:10.1038/s41385-
1175 020-00340-z
1176 10.1038/s41385-020-00340-z [pii] (2020).

1177 39 Khoury, D. S. *et al.* Measuring immunity to SARS-CoV-2 infection: comparing
1178 assays and animal models. *Nat Rev Immunol* **20**, 727-738,
1179 doi:10.1038/s41577-020-00471-1
1180 10.1038/s41577-020-00471-1 [pii] (2020).

1181 40 10x Genomics. *Can I process neutrophils (or other granulocytes) using 10x*
1182 *Single Cell applications?*, <[https://kb.10xgenomics.com/hc/en-](https://kb.10xgenomics.com/hc/en-us/articles/360004024032-Can-I-process-neutrophils-or-other-granulocytes-using-10x-Single-Cell-applications-)
1183 [us/articles/360004024032-Can-I-process-neutrophils-or-other-granulocytes-](https://kb.10xgenomics.com/hc/en-us/articles/360004024032-Can-I-process-neutrophils-or-other-granulocytes-using-10x-Single-Cell-applications-)
1184 [using-10x-Single-Cell-applications->](https://kb.10xgenomics.com/hc/en-us/articles/360004024032-Can-I-process-neutrophils-or-other-granulocytes-using-10x-Single-Cell-applications-) (2020).

1185 41 Dietert, K. *et al.* Spectrum of pathogen- and model-specific histopathologies in
1186 mouse models of acute pneumonia. *PLoS One* **12**, e0188251,
1187 doi:10.1371/journal.pone.0188251
1188 PONE-D-17-27356 [pii] (2017).

1189 42 Fu, J. *et al.* The clinical implication of dynamic neutrophil to lymphocyte ratio
1190 and D-dimer in COVID-19: A retrospective study in Suzhou China. *Thromb*
1191 *Res* **192**, 3-8, doi:S0049-3848(20)30169-9 [pii]
1192 10.1016/j.thromres.2020.05.006 (2020).

1193 43 Middleton, E. A. *et al.* Neutrophil extracellular traps contribute to
1194 immunothrombosis in COVID-19 acute respiratory distress syndrome. *Blood*
1195 **136**, 1169-1179, doi:10.1182/blood.2020007008
1196 461219 [pii] (2020).

1197 44 Schulte-Schrepping, J. *et al.* Severe COVID-19 Is Marked by a Dysregulated
1198 Myeloid Cell Compartment. *Cell* **182**, 1419-1440 e1423, doi:S0092-
1199 8674(20)30992-2 [pii]
1200 10.1016/j.cell.2020.08.001 (2020).

1201 45 Hönzke, K. *et al.* Human Lungs Show Limited Permissiveness for SARS-CoV-
1202 2 Due to Scarce ACE2 Levels But Strong Virus-Induced Immune Activation in
1203 Alveolar Macrophages. *SSRN*, doi:10.2139/ssrn.3687020 (2020).

1204 46 Speranza, E. *et al.* SARS-CoV-2 Infection Dynamics in Lungs of African Green
1205 Monkeys. *SSRN*, doi:10.2139/ssrn.3681984 (2020).

1206 47 Van Strijp, J. A., Van Kessel, K. P., van der Tol, M. E. & Verhoef, J.
1207 Complement-mediated phagocytosis of herpes simplex virus by granulocytes.
1208 Binding or ingestion. *J Clin Invest* **84**, 107-112, doi:10.1172/JCI114129 (1989).

1209 48 Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-
1210 19: a key role for monocytes and macrophages. *Nat Rev Immunol* **20**, 355-
1211 362, doi:10.1038/s41577-020-0331-4
1212 10.1038/s41577-020-0331-4 [pii] (2020).

1213 49 V'Kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus
1214 biology and replication: implications for SARS-CoV-2. *Nat Rev Microbiol*,
1215 doi:10.1038/s41579-020-00468-6
1216 10.1038/s41579-020-00468-6 [pii] (2020).

1217 50 Fiege, J. K. *et al.* Single cell resolution of SARS-CoV-2 tropism, antiviral
1218 responses, and susceptibility to therapies in primary human airway epithelium.
1219 *bioRxiv*, 2020.2010.2019.343954, doi:10.1101/2020.10.19.343954 (2020).

1220 51 Wyler, E. *et al.* Bulk and single-cell gene expression profiling of SARS-CoV-2
1221 infected human cell lines identifies molecular targets for therapeutic
1222 intervention. *bioRxiv*, 2020.2005.2005.079194,
1223 doi:10.1101/2020.05.05.079194 (2020).

1224 52 Escher, R., Breakey, N. & Lammle, B. Severe COVID-19 infection associated
1225 with endothelial activation. *Thromb Res* **190**, 62, doi:S0049-3848(20)30130-4
1226 [pii]
1227 10.1016/j.thromres.2020.04.014 (2020).

1228 53 Marchetti, M. COVID-19-driven endothelial damage: complement, HIF-1, and
1229 ABL2 are potential pathways of damage and targets for cure. *Ann Hematol* **99**,
1230 1701-1707, doi:10.1007/s00277-020-04138-8
1231 10.1007/s00277-020-04138-8 [pii] (2020).

1232 54 Thompson, B. T., Chambers, R. C. & Liu, K. D. Acute Respiratory Distress
1233 Syndrome. *N Engl J Med* **377**, 562-572, doi:10.1056/NEJMra1608077 (2017).

1234 55 To, K. F. & Lo, A. W. Exploring the pathogenesis of severe acute respiratory
 1235 syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and
 1236 its putative receptor, angiotensin-converting enzyme 2 (ACE2). *J Pathol* **203**,
 1237 740-743, doi:10.1002/path.1597 (2004).
 1238 56 Janice Oh, H. L., Ken-En Gan, S., Bertoletti, A. & Tan, Y. J. Understanding the
 1239 T cell immune response in SARS coronavirus infection. *Emerg Microbes Infect*
 1240 **1**, e23, doi:10.1038/emi.2012.26 (2012).
 1241 57 Shin, H. S. *et al.* Immune Responses to Middle East Respiratory Syndrome
 1242 Coronavirus During the Acute and Convalescent Phases of Human Infection.
 1243 *Clin Infect Dis* **68**, 984-992, doi:10.1093/cid/ciy595
 1244 5060259 [pii] (2019).
 1245 58 Varchetta, S. *et al.* Unique immunological profile in patients with COVID-19.
 1246 *Cell Mol Immunol*, doi:10.1038/s41423-020-00557-9
 1247 10.1038/s41423-020-00557-9 [pii] (2020).
 1248 59 Peng, Y. *et al.* Broad and strong memory CD4(+) and CD8(+) T cells induced
 1249 by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nat*
 1250 *Immunol* **21**, 1336-1345, doi:10.1038/s41590-020-0782-6
 1251 10.1038/s41590-020-0782-6 [pii] (2020).
 1252 60 Gudbjartsson, D. F. *et al.* Humoral Immune Response to SARS-CoV-2 in
 1253 Iceland. *N Engl J Med* **383**, 1724-1734, doi:10.1056/NEJMoa2026116 (2020).
 1254 61 Ni, L. *et al.* Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity
 1255 in COVID-19 Convalescent Individuals. *Immunity* **52**, 971-977 e973,
 1256 doi:S1074-7613(20)30181-3 [pii]
 1257 10.1016/j.immuni.2020.04.023 (2020).
 1258 62 Mammoto, A. & Mammoto, T. Vascular Niche in Lung Alveolar Development,
 1259 Homeostasis, and Regeneration. *Front Bioeng Biotechnol* **7**, 318,
 1260 doi:10.3389/fbioe.2019.00318 (2019).
 1261 63 Niethamer, T. K. *et al.* Defining the role of pulmonary endothelial cell
 1262 heterogeneity in the response to acute lung injury. *Elife* **9**,
 1263 doi:10.7554/eLife.53072
 1264 e53072 [pii]
 1265 53072 [pii] (2020).

1266 64 Palumbo-Zerr, K. *et al.* Orphan nuclear receptor NR4A1 regulates
1267 transforming growth factor-beta signaling and fibrosis. *Nat Med* **21**, 150-158,
1268 doi:10.1038/nm.3777
1269 nm.3777 [pii] (2015).

1270 65 Lee, H. S. *et al.* Altered AKAP12 expression in portal fibroblasts and liver
1271 sinusoids mediates transition from hepatic fibrogenesis to fibrosis resolution.
1272 *Exp Mol Med* **50**, 48, doi:10.1038/s12276-018-0074-5
1273 10.1038/s12276-018-0074-5 [pii] (2018).

1274 66 Cao, Z. *et al.* Targeting of the pulmonary capillary vascular niche promotes
1275 lung alveolar repair and ameliorates fibrosis. *Nat Med* **22**, 154-162,
1276 doi:10.1038/nm.4035
1277 nm.4035 [pii] (2016).

1278 67 Wolfel, R. *et al.* Virological assessment of hospitalized patients with COVID-
1279 2019. *Nature* **581**, 465-469, doi:10.1038/s41586-020-2196-x
1280 10.1038/s41586-020-2196-x [pii] (2020).

1281 68 Corman, V. M. *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-
1282 time RT-PCR. *Euro Surveill* **25**, doi:10.2807/1560-
1283 7917.ES.2020.25.3.2000045 (2020).

1284 69 Muller, T. *et al.* Automated sample preparation with SP3 for low-input clinical
1285 proteomics. *Mol Syst Biol* **16**, e9111, doi:10.15252/msb.20199111 (2020).

1286 70 Messner, C. B. *et al.* Scanning SWATH acquisition enables high-throughput
1287 proteomics with chromatographic gradients as fast as 30 seconds. *bioRxiv*,
1288 656793, doi:10.1101/656793 (2020).

1289 71 Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-
1290 NN: neural networks and interference correction enable deep proteome
1291 coverage in high throughput. *Nat Methods* **17**, 41-44, doi:10.1038/s41592-
1292 019-0638-x (2020).

1293 72 Cox, J. *et al.* Accurate proteome-wide label-free quantification by delayed
1294 normalization and maximal peptide ratio extraction, termed MaxLFQ. *Mol Cell*
1295 *Proteomics* **13**, 2513-2526, doi:10.1074/mcp.M113.031591 (2014).

1296 73 Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-
1297 sequencing and microarray studies. *Nucleic Acids Res* **43**, e47,
1298 doi:10.1093/nar/gkv007 (2015).

1299 74 Kolberg, L. & Raudvere, U. gprofiler2: Interface to the 'g:Profiler' Toolset.
 1300 (2020).
 1301 75 Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the
 1302 integration of genomic datasets with the R/Bioconductor package biomaRt.
 1303 *Nat Protoc* **4**, 1184-1191, doi:10.1038/nprot.2009.97
 1304 nprot.2009.97 [pii] (2009).
 1305 76 Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based
 1306 genome alignment and genotyping with HISAT2 and HISAT-genotype. *Nat*
 1307 *Biotechnol* **37**, 907-915, doi:10.1038/s41587-019-0201-4
 1308 10.1038/s41587-019-0201-4 [pii] (2019).
 1309 77 Gaidatzis, D., Lerch, A., Hahne, F. & Stadler, M. B. QuasR: quantification and
 1310 annotation of short reads in R. *Bioinformatics* **31**, 1130-1132,
 1311 doi:10.1093/bioinformatics/btu781
 1312 btu781 [pii] (2015).
 1313 78 Zyla, J. *et al.* Gene set enrichment for reproducible science: comparison of
 1314 CERNO and eight other algorithms. *Bioinformatics* **35**, 5146-5154,
 1315 doi:10.1093/bioinformatics/btz447
 1316 5511403 [pii] (2019).
 1317 79 Liberzon, A. *et al.* The Molecular Signatures Database (MSigDB) hallmark
 1318 gene set collection. *Cell Syst* **1**, 417-425, doi:10.1016/j.cels.2015.12.004
 1319 S2405-4712(15)00218-5 [pii] (2015).
 1320 80 R: A language and environment for statistical computing (R Foundation for
 1321 Statistical Computing, Vienna, Austria, 2019).
 1322 81 Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating
 1323 single-cell transcriptomic data across different conditions, technologies, and
 1324 species. *Nat Biotechnol* **36**, 411-420, doi:10.1038/nbt.4096 (2018).
 1325 82 Wickham, H. *et al.* Welcome to the Tidyverse. *Journal of Open Source*
 1326 *Software* **4**, 1686, doi:10.21105/joss.01686 (2019).
 1327 83 Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects
 1328 Models Using lme4. *Journal of Statistical Software; Vol 1, Issue 1* (2015),
 1329 doi:10.18637/jss.v067.i01 (2015).
 1330 84 Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**,
 1331 1888-1902 e1821, doi:S0092-8674(19)30559-8 [pii]
 1332 10.1016/j.cell.2019.05.031 (2019).

1333 85 Tabula Muris Consortium. Single-cell transcriptomics of 20 mouse organs
1334 creates a Tabula Muris. *Nature* **562**, 367-372, doi:10.1038/s41586-018-0590-4
1335 10.1038/s41586-018-0590-4 [pii] (2018).

1336 86 Travaglini, K. J. *et al.* A molecular cell atlas of the human lung from single-cell
1337 RNA sequencing. *Nature* **587**, 619-625, doi:10.1038/s41586-020-2922-4
1338 10.1038/s41586-020-2922-4 [pii] (2020).

1339 87 Franzen, O., Gan, L. M. & Bjorkegren, J. L. M. PanglaoDB: a web server for
1340 exploration of mouse and human single-cell RNA sequencing data. *Database*
1341 (*Oxford*) **2019**, doi:baz046 [pii]
1342 10.1093/database/baz046
1343 5427041 [pii] (2019).

1344 88 Zhang, X. *et al.* CellMarker: a manually curated resource of cell markers in
1345 human and mouse. *Nucleic Acids Res* **47**, D721-D728,
1346 doi:10.1093/nar/gky900
1347 5115823 [pii] (2019).

1348 89 Han, X. *et al.* Mapping the Mouse Cell Atlas by Microwell-Seq. *Cell* **172**, 1091-
1349 1107 e1017, doi:S0092-8674(18)30116-8 [pii]
1350 10.1016/j.cell.2018.02.001 (2018).

1351 90 Angelidis, I. *et al.* An atlas of the aging lung mapped by single cell
1352 transcriptomics and deep tissue proteomics. *Nat Commun* **10**, 963,
1353 doi:10.1038/s41467-019-08831-9
1354 10.1038/s41467-019-08831-9 [pii] (2019).

1355 91 Lechner, A. J. *et al.* Recruited Monocytes and Type 2 Immunity Promote Lung
1356 Regeneration following Pneumonectomy. *Cell Stem Cell* **21**, 120-134 e127,
1357 doi:S1934-5909(17)30095-4 [pii]
1358 10.1016/j.stem.2017.03.024 (2017).

1359 92 Shaheen, Z. R. *et al.* CCR5 is a required signaling receptor for macrophage
1360 expression of inflammatory genes in response to viral double-stranded RNA.
1361 *Am J Physiol Regul Integr Comp Physiol* **316**, R525-R534,
1362 doi:10.1152/ajpregu.00019.2019 (2019).

1363 93 Briseno, C. G. *et al.* Distinct Transcriptional Programs Control Cross-Priming
1364 in Classical and Monocyte-Derived Dendritic Cells. *Cell Rep* **15**, 2462-2474,
1365 doi:10.1016/j.celrep.2016.05.025
1366 S2211-1247(16)30593-9 [pii] (2016).

- 94 Zhao, Y. *et al.* Single-cell transcriptomic landscape of nucleated cells in
umbilical cord blood. *Gigascience* **8**, doi:giz047 [pii]
10.1093/gigascience/giz047
5484799 [pii] (2019).
- 95 Dutertre, C. A. *et al.* Single-Cell Analysis of Human Mononuclear Phagocytes
Reveals Subset-Defining Markers and Identifies Circulating Inflammatory
Dendritic Cells. *Immunity* **51**, 573-589 e578, doi:S1074-7613(19)30334-6 [pii]
10.1016/j.immuni.2019.08.008 (2019).
- 96 Monaghan, K. L., Zheng, W., Hu, G. & Wan, E. C. K. Monocytes and
Monocyte-Derived Antigen-Presenting Cells Have Distinct Gene Signatures in
Experimental Model of Multiple Sclerosis. *Front Immunol* **10**, 2779,
doi:10.3389/fimmu.2019.02779 (2019).
- 97 Rodrigues, P. F. *et al.* Distinct progenitor lineages contribute to the
heterogeneity of plasmacytoid dendritic cells. *Nat Immunol* **19**, 711-722,
doi:10.1038/s41590-018-0136-9
10.1038/s41590-018-0136-9 [pii] (2018).
- 98 Raredon, M. S. B. *et al.* Single-cell connectomic analysis of adult mammalian
lungs. *Sci Adv* **5**, eaaw3851, doi:10.1126/sciadv.aaw3851
aaw3851 [pii] (2019).
- 99 Smith, S. L. *et al.* Diversity of peripheral blood human NK cells identified by
single-cell RNA sequencing. *Blood Adv* **4**, 1388-1406,
doi:10.1182/bloodadvances.2019000699
454300 [pii] (2020).
- 100 Zhu, P. *et al.* The cytotoxic T lymphocyte protease granzyme A cleaves and
inactivates poly(adenosine 5'-diphosphate-ribose) polymerase-1. *Blood* **114**,
1205-1216, doi:10.1182/blood-2008-12-195768
blood-2008-12-195768 [pii] (2009).
- 101 Cohen, M. *et al.* Lung Single-Cell Signaling Interaction Map Reveals Basophil
Role in Macrophage Imprinting. *Cell* **175**, 1031-1044 e1018, doi:S0092-
8674(18)31181-4 [pii]
10.1016/j.cell.2018.09.009 (2018).
- 102 Tawfik, O. *et al.* Transgelin, a Novel Marker of Smooth Muscle Differentiation,
Effectively Distinguishes Endometrial Stromal Tumors from Uterine Smooth
Muscle Tumors. *Int J Gynecol Obstet Reprod Med Res* **1**, 26-31 (2014).

- 103 Barbour, R. *et al.* Red blood cells are the major source of alpha-synuclein in blood. *Neurodegener Dis* **5**, 55-59, doi:10.1159/000112832 (2008).
- 104 Chiabrando, D., Mercurio, S. & Tolosano, E. Heme and erythropoiesis: more than a structural role. *Haematologica* **99**, 973-983, doi:10.3324/haematol.2013.091991 (2014).
- 105 Durussel, J. *et al.* Blood transcriptional signature of recombinant human erythropoietin administration and implications for antidoping strategies. *Physiol Genomics* **48**, 202-209, doi:10.1152/physiolgenomics.00108.2015 (2016).
- 106 Burgess, M., Wicks, K., Gardasevic, M. & Mace, K. A. Cx3CR1 Expression Identifies Distinct Macrophage Populations That Contribute Differentially to Inflammation and Repair. *Immunohorizons* **3**, 262-273, doi:10.4049/immunohorizons.1900038 (2019).
- 107 Cochain, C. *et al.* Single-Cell RNA-Seq Reveals the Transcriptional Landscape and Heterogeneity of Aortic Macrophages in Murine Atherosclerosis. *Circ Res* **122**, 1661-1674, doi:10.1161/CIRCRESAHA.117.312509 (2018).
- 108 Ronning, K. E., Karlen, S. J., Miller, E. B. & Burns, M. E. Molecular profiling of resident and infiltrating mononuclear phagocytes during rapid adult retinal degeneration using single-cell RNA sequencing. *Sci Rep* **9**, 4858, doi:10.1038/s41598-019-41141-0 (2019).
- 109 Kim, M. H. *et al.* A late-lineage murine neutrophil precursor population exhibits dynamic changes during demand-adapted granulopoiesis. *Sci Rep* **7**, 39804, doi:10.1038/srep39804 srep39804 [pii] (2017).
- 110 Xie, X. *et al.* Single-cell transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection. *Nat Immunol* **21**, 1119-1133, doi:10.1038/s41590-020-0736-z 10.1038/s41590-020-0736-z [pii] (2020).
- 111 Zuccolo, J. *et al.* Expression of MS4A and TMEM176 Genes in Human B Lymphocytes. *Front Immunol* **4**, 195, doi:10.3389/fimmu.2013.00195 (2013).
- 112 El-Gedaily, A., Schoedon, G., Schneemann, M. & Schaffner, A. Constitutive and regulated expression of platelet basic protein in human monocytes. *J Leukoc Biol* **75**, 495-503, doi:10.1189/jlb.0603288 jlb.0603288 [pii] (2004).

1435 113 Sampath, P., Moideen, K., Ranganathan, U. D. & Bethunaickan, R. Monocyte
1436 Subsets: Phenotypes and Function in Tuberculosis Infection. *Front Immunol* **9**,
1437 1726, doi:10.3389/fimmu.2018.01726 (2018).
1438 114 Praktijnjo, S. D. *et al.* Tracing tumorigenesis in a solid tumor model at single-
1439 cell resolution. *Nat Commun* **11**, 991, doi:10.1038/s41467-020-14777-0
1440 10.1038/s41467-020-14777-0 [pii] (2020).
1441

Figures

Figure 1

Single-cell dynamics in lungs and blood of SARS-CoV-2 infected Syrian hamsters (a), UMAP plot of identified cell populations in Syrian hamster lungs. (b), Cell count of isolated cells per lung lobe over time (2, 3, 5 and 14 dpi) and control group (naïve, “d0”). (c), Count of hematopoietic cells per lung lobe in naïve

hamsters and over time pi. (d), Changes in cellular density of lung cells in UMAP projection. Coloration indicates log2 fold change between control group and 5 dpi. (e), Percentage of hematopoietic cells per lung lobe in naïve hamsters and over time pi. (f), UMAP plot of identified cell populations in blood samples. (g), Cell count of isolated cells per mL blood in naïve hamsters and over time pi. (h), Percentage of identified cell populations in blood samples over time pi and naïve animals. (i), Neutrophil–lymphocyte ratio in blood samples over time pi and naïve animals. (a, d and f), Clusters defined by Louvain clustering, n = 3 per time point. (b, c, e, g, h and i), Data display means $\pm$ SD. n = 3 per time point. Ordinary one-way ANOVA, Sidak's multiple comparisons test versus corresponding 0 dpi (naïve). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

Figure 2

Proteomics analysis recapitulates transcriptomics and human COVID-19 patient data (a), Temporal evolution of gene ontology/biological process terms connected with immune system response in lung tissue (left part) and in serum fluid (right part), for the indicated time points compared to samples from uninfected animals. Enriched terms were filtered for terms mentioning “immune”, “interferon”, “neutrophil”, “T cell” and “B cell”. Size of dots correspond to the inverse of the false discovery rate. (b), Expression values for differentially regulated proteins in hamster serum (control 3 dpi, p value < 0.01) and

lung (control 5 dpi, p value < 0.01) that correlate with disease severity in human plasma. Controls from different days are plotted together. The thick line represents median of all values, lower and upper hinges correspond to medians of lower and upper half of set, respectively. Whiskers extend to a maximum of 1.5 times distance between first and third quartile. All values are shown. (c) Expression values for the differentially expressed proteins Lgals3 and Lgals3bp (only detected in lung samples).

Figure 3

Induction of inflammatory mediators are strongest and earliest in myeloid cells Dotplots of differentially expressed cytokines and inflammatory mediators in lungs. Shown are genes that display a significant

absolute log2-transformed fold change of at least one in at least one comparison, and are grouped into four categories indicated on the left. Coloration and point size indicate log2-transformed fold changes and P values, respectively, of genes at 2 dpi relative to control groups (naïve). Adjusted P values were calculated by DEseq2 using Benjamini-Hochberg corrections of Wald test p values. Genes are ordered by unsupervised clustering, cell type as in Figure 1.

Figure 4

Transcriptional response to SARS-CoV-2 infection is strong in myeloid and moderate in epithelial cells (a, b), Dotplot of differentially expressed genes in lungs (a) and blood (b). Shown are genes that are in at least one cell type among the top 4 most changing genes as ranked by adjusted p value. Example: top 4 most changing genes in alveolar macrophages are Ybx3, Rps15, Rps10, and Uba52. Coloration and point

size indicate log₂-transformed fold changes and p values, respectively, of genes at 2 dpi relative to control groups (naïve). Adjusted p values were calculated by DEseq2 using Benjamini-Hochberg corrections of Wald test p values. Cell types and genes are ordered by unsupervised clustering. (c), Top, fraction of monocytic macrophages expressing Cxcl10 in blood and lungs from naïve animals and 2 dpi. Bottom, boxplots of Cxcl10 gene expression values of cells positive for Cxcl10 expression. Significance levels were calculated using generalized linear mixed-effects models for bar plot and a Wilcoxon rank sum test on all cells (i.e. not only the ones expressing the gene) for boxplots. * means p value 0.05-0.01, ** means p value 0.01-0.0001, *** means p value smaller 0.0001. See materials and methods for details. (d), As in (c), but only in lungs, all time points and both alveolar epithelial cells type 2 (AT2) and monocytic macrophages. Displayed are values for Isg15 (left) and Cxcl10 (right). For all bar plots, data display means $\pm$ SD, n = 3 per time point. For all boxplots, lower and upper hinges correspond to first and third quartiles. Whiskers extend to a maximum of 1.5 times the distance between first and third quartile. Outliers beyond are marked by single dots.

Figure 5

Virus RNA in monocytic macrophages leads to dose-dependent activation of pro-inflammatory cytokines by TLR signaling. (a), Feature plots of entry factor expression in UMAP projection. Coloration indicates expression values of indicated genes. (b-e), Detection of viral RNA by in situ688 hybridization. Labeled are supposed endothelium (b, hash), bronchial epithelial cells (b, arrowhead), AT1 (c, arrowhead) and AT2 (c, arrow). (d, inset), macrophages containing viral RNA and cell debris (arrowhead), and an example of high levels of viral RNA without cell debris in the inset (arrow). For (b-e), red signals viral RNA and blue hemalaun counterstain. Time points: (b-c) from 2 dpi, (d) from 3 dpi, (e) staining control. Bars: (b, d, e) = 50 μ m, (c) = 100 μ m, Inset in (c) = 20 μ m. (f), Cells in the UMAP projection are colored by amount of viral RNA (log10 transformed percentage of viral RNA per cell), along with overview of

identified cell types in lungs. (g), Dotplot of cytokine expression in monocytic macrophages containing viral RNA compared to those without viral RNA. Coloration and point size indicate log2 fold change and P value for each time point 2, 3 and 5 dpi. (h, i), Box- and barplots of *Isg15* (h) and *Cxcl10* (i) gene expression in AT2 and monocytic macrophages along, comparing cells containing viral RNA to those without for 2, 3, and 5 dpi. Barplot shows percentage of cells positive for respective gene, with mean $\pm$ SD, n = 3. Boxplots show gene expression levels in cells positive for respective gene. (j), Box- and barplots of *Cxcl10* in monocytic macrophages and fraction of *Cxcl10* 703 positive cells for each time point pi and naïve animals, with cells grouped by increasing virus levels for 2, 3, and 5 dpi. (e and f), for barplots, data display means $\pm$ SD. Significance levels calculated using generalized linear mixed-effects models for barplot and a wilcoxon rank sum test on all cells (i.e. not only the ones expressing the gene) for boxplots. $\square$ P < 0.05, $\square\square$ P < 0.01, $\square\square\square$ P < 0.001, $\square\square\square\square$ P < 0.0001. See materials and methods for details.

Figure 6

Endothelial cells show subtype and time specific activation of cytokines (a), UMAP plot of lung endothelial cell subpopulations. (b), Dotplot of differentially expressed genes in lung endothelial cell subpopulations over time. Shown are genes that are in at least one cell type among the top 10 most changing genes as ranked by adjusted p value. (c), Dotplot of differentially expressed genes from two curated sets as indicated in lung endothelial cell subpopulations over time pi. For both (b) and (c), coloration and point size indicate log2-transformed fold changes and P values, respectively, of genes at 2 dpi relative to control groups (naïve). Adjusted p values were calculated by DEseq2 using Benjamini-Hochberg corrections of Wald test p values.

Figure 7

Syrian hamsters exhibit a strong cytotoxic T/NK cell response at day 5 post infection. (a), UMAP plot of lung T/NK cell subclustering indicating cell subpopulations. (b), Count of lung T cell subpopulations and NK cells per lung lobe. (c), Dotplot of master regulators of T cell differentiation and effector genes. Coloration and point size indicate log2 fold change and P value, respectively. (d), Fraction of Ifng⁺ cells in CD4⁺ T, CD8⁺ T and NK cells at 2, 3, 5 and 14 dpi and naïve. (e), Fraction of Gzma⁺ cells in CD8⁺ T

cells at 2, 3, 5 and 14 dpi and naïve. (f), Fraction of AT2 cells, monocytic macrophages, endothelial cells and AT1 cells containing both at least one cell type marker gene (AT2: Sftpa1, Sftpc – monocytic macrophages: Fcn1, Saa3 – endothelial cells: Cldn5, Plvap – AT1: Ager, Aqp5) together with Gzma. Data display means $\pm$ SD, n = 3 per time point. (g), Histopathology of blood vessels at different time points, bar: 50 μ m. (h) Serum neutralization titers of SARS-CoV-2 infected hamsters at 5 and 14 dpi. Serum titers of naïve, 2 and 3 dpi did 736 not neutralize up to detection limit 1:4 (dotted line). Data display n = 3 with mean per time point.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [HamsterNouailllessuppsNComms.pdf](#)